

slark note

L4 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:354682 CAPLUS Full-text
DN 140:375195
TI Tetrazolylpropionamides as inhibitors of A β protein production
IN Yang, Michael G.
PA USA
SO U.S. Pat. Appl. Publ., 52 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004082568	A1	20040429	US 2003-650358	20030827
PRAI	US 2002-406144P	P	20020827		
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alk(en/yn)yl; R3, R5 = H, amino, alk(en/yn)yl, etc.; R3a, R5a = H, alk(en)yl, etc.; R6 = H, alkyl; B = 7-membered lactam, etc.; W = bond, CH2, CH2CH2; X = bond, Ph, pyridyl, etc.; Y = bond, CO, O, S, etc.; Z = H, alk(en/yn)yl, etc.] are prepared For example, (R)-4-methyl-2-((1-propyl-1H-tetrazol-5-yl)methyl)pentanoic acid (preparation given) is coupled to a substituted benzodiazepine (DMF, HATu, i-Pr2NEt) to give II. Compds. of the invention exhibit IC50 < 10 μ M for γ -secretase. I inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A β -peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein. I are useful for the treatment of neurol. disorders related to β -amyloid production, such as Alzheimer's disease and Down's Syndrome.

IT 682812-68-6P 682813-01-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); REP (Preparation); USES (Uses)

(preparation of benzodiazepinones as inhibitors of A β production for treatment of Alzheimer's disease and Down's syndrome)


RN 682812-68-6 CAPLUS

CN 1H-Tetrazole-5-propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- β -methyl- α -(2-methylpropyl)-1-propyl-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 682813-01-0 CAPLUS
CN 1H-Tetrazole-5-propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-β-methyl-α-(2-methylpropyl)-1-propyl-(9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:292545 CAPLUS Full-text

DN 140:368548

TI Studies of A β pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the γ -secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)

AU Lanz, Thomas A.; Hosley, John D.; Adams, Wade J.; Merchant, Kalpana M.

CS Department of Neurobiology, Pharmacia Corporation, Kalamazoo, MI, USA

SO Journal of Pharmacology and Experimental Therapeutics (2004), 309(1), 49-55

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB A previous study by us suggests the utility of cerebrospinal fluid (CSF) and plasma A β as biomarkers of β - or γ -secretase inhibition. The present study characterized further A β pharmacodynamics in these tissues from Tg2576 mice and examined their correlation with brain A β after acute treatment with a potent γ -secretase inhibitor, N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). A single dose of LY-411575 dose-dependently (0.1 - 10 mg/kg p.o.) reduced A β (1 - 40) and A β (1 - 42) in the CSF and the brain. In contrast, plasma A β levels were increased by 0.1 mg/kg LY-411575 and were followed by a dose-dependent reduction at higher doses. The time courses of A β reduction and recovery were distinct for the three tissues: maximal declines in A β levels were evident by 3 h in the CSF and plasma but not until 9 h in the brain. A recovery in A β levels was underway in the CSF by 9 h and nearly completed by 24 h in all tissues. The differential time courses in the three compartments do not seem to be due to pharmacokinetic factors. Five days of twice-daily treatment with LY-411575 not only sustained the A β redns. in all tissues but also significantly augmented the efficacy in the brain and plasma. The increased efficacy occurred in the absence of compound accumulation and was consistent with the recovery rates in each compartment. Overall, A β in the CSF and not plasma seems to be a better biomarker of brain A β reduction; however, the time course of A β changes needs to be established in clin. studies.

IT 209984-57-6, LY 411575


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(A β pharmacodynamics in brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the γ -secretase inhibitor LY-411575)

RN 209984-57-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:239373 CAPLUS Full-text
 DN 141:1035
 TI Chronic Treatment with the γ -Secretase Inhibitor LY-411575 Inhibits
 β -Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal
 Cell Differentiation
 AU Wong, Gwendolyn T.; Manfra, Denise; Poulet, Frederique M.; Zhang, Qi;
 Josien, Hubert; Bara, Thomas; Engstrom, Laura; Pinzon-Ortiz, Maria;
 Fine, Jay S.; Lee, Hu-Jung J.; Zhang, Lili; Higgins, Guy A.; Parker,
 Eric M.
 CS Chemical Research, Immunology, Departments of Central Nervous System
 Research, Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
 SO Journal of Biological Chemistry (2004), 279(13), 12876-12882
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 AB Inhibition of γ -secretase, one of the enzymes responsible for the
 cleavage of the amyloid precursor protein (APP) to produce the
 pathogenic β -amyloid ($A\beta$) peptides, is an attractive approach to the
 treatment of Alzheimer disease. In addition to APP, however, several
 other γ -secretase substrates have been identified (e.g. Notch), and
 altered processing of these substrates by γ -secretase inhibitors could
 lead to unintended biol. consequences. To study the in vivo
 consequences of γ -secretase inhibition, the γ -secretase inhibitor LY-
 411575 was administered to C57BL/6 and TgCRND8 APP transgenic mice for
 15 days. Although most tissues were unaffected, doses of LY-411575 that
 inhibited $A\beta$ production had marked effects on lymphocyte development and
 on the intestine. LY-411575 decreased overall thymic cellularity and
 impaired intrathymic differentiation at the CD4-CD8-CD44+CD25+ precursor
 stage. No effects on peripheral T cell populations were noted following
 LY-411575 treatment, but evidence for the altered maturation of
 peripheral B cells was observed. In the intestine, LY-411575 treatment
 increased goblet cell number and drastically altered tissue morphol.
 These effects of LY-411575 were not seen in mice that were administered
 LY-D, a diastereoisomer of LY-411575, which is a very weak γ -secretase
 inhibitor. These studies show that inhibition of γ -secretase has the
 expected benefit of reducing $A\beta$ in a murine model of Alzheimer disease
 but has potentially undesirable biol. effects as well, most likely
 because of the inhibition of Notch processing.
 IT 209984-57-6, LY 411575
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (chronic treatment with the γ -secretase inhibitor LY-411575
 inhibits β -amyloid peptide production and alters lymphopoiesis and
 intestinal cell differentiation)
 RN 209984-57-6 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -
 hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 693788-17-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chronic treatment with the γ -secretase inhibitor LY-411575 inhibits β -amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation)

RN 693788-17-9 CAPLUS



CN Benzeneacetamide, N-[(1S)-2-[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:153513 CAPLUS Full-text
 DN 140:375058
 TI Highly efficient synthesis of medium-sized lactams via intramolecular
 Staudinger-aza-Wittig reaction of ω -azido pentafluorophenyl ester:
 synthesis and biological evaluation of LY411575 analogues
 AU Fuwa, Haruhiko; Okamura, Yumiko; Morohashi, Yuichi; Tomita, Taisuke;
 Iwatsubo, Takeshi; Kan, Toshiyuki; Fukuyama, Tohru; Natsugari, Hideaki
 CS Graduate School of Pharmaceutical Sciences, The University of Tokyo,
 Bunkyo-ku, Tokyo, 113-0033, Japan
 SO Tetrahedron Letters (2004), 45(11), 2323-2326
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science B.V.
 DT Journal
 LA English
 GI



AB A highly efficient method for the synthesis of medium-sized lactams
 based on intramol. Staudinger-aza-Wittig reaction of ω -azido
 pentafluorophenyl ester has been developed. A variety of 7-10 membered
 lactams, e.g., I, were synthesized in excellent yields. Application of
 the method to the synthesis of analogs of a potent γ -secretase inhibitor
 LY411575, e.g., II, and their biol. evaluation are also described.
 IT **683277-96-5P 683277-97-6P 683277-99-8P**
683278-00-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent) (preparation and γ -secretase inhibition activity of
 LY411575 analogs employing lactams generated via intramol. Staudinger-
 aza-Wittig reaction of ω -azido pentafluorophenyl esters)
 RN 683277-96-5 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-5-methyl-6-oxo-3-
 (phenylmethoxy)-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-
 3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 683277-97-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-5-methyl-6-oxo-2-(phenylmethoxy)-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 683277-99-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-3-hydroxy-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 683278-00-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-2-hydroxy-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-57-6DP, LY 411575, Analogs 683277-95-4P
 683278-01-5P 683278-02-6P 683278-03-7P
 683278-04-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)

(preparation and γ -secretase inhibition activity of LY411575 analogs
 employing lactams generated via intramol. Staudinger-aza-Wittig
 reaction of ω -azido pentafluorophenyl esters)

RN 209984-57-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -
 hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 683277-95-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 683278-01-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[3-[(4-benzoylphenyl)methoxy]-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 683278-02-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[2-[(4-benzoylphenyl)methoxy]-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 683278-03-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-3-methoxy-5-methyl-6-oxo-5H-dibenzo[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 683278-04-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-2-methoxy-5-methyl-6-oxo-5H-dibenzo[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:415932 CAPLUS Full-text

DN 139:127922

TI Catalytic Site-Directed γ -Secretase Complex Inhibitors Do Not
Discriminate Pharmacologically between Notch S3 and β -APP Cleavages

AU Lewis, Huw D.; Perez Revuelta, Blanca I. Perez; Nadin, Alan; Neduvelil,
Joe G.; Harrison, Timothy; Pollack, Scott J.; Shearman, Mark S.

CS Departments of Biochemistry and Molecular Biology and Medicinal
Chemistry,

The Neuroscience Research Centre, Merck Sharp Dohme Research
Laboratories,

Harlow Essex, CM20 2QR, UK

SO Biochemistry (2003), 42(24), 7580-7586

CODEN: BICHAW; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

AB The generation of γ -secretase inhibitors which block the release of β -amyloid peptide ($A\beta$) has long been an attractive therapeutic avenue for treatment or prevention of Alzheimer's disease (AD). Such inhibitors would reduce levels of $A\beta$ available for aggregation into toxic assemblies that lead to the plaque pathol. found in affected brain tissue. Cumulative evidence suggests that the S3 cleavage of Notch is also dependent on presenilins (PS) and is carried out by the multimeric PS-containing γ -secretase complex. It is therefore possible that Notch function could be affected by γ -secretase inhibitors. To assess the relation between the cleavage of these substrates in the same system, Western blot cleavage assays have been established using a human cell line stably expressing both the β -amyloid precursor protein (β -APP) and the truncated Notch1 receptor fragment Notch ΔE . Thus, a direct correlation may be made, following inhibitor treatment, of the decrease in the levels of the cleavage products, $A\beta$ peptide and the Notch intracellular domain (NICD), as well as the increase in stabilized levels of both substrates. This anal. has been performed with a range of selected γ -secretase inhibitors from six distinct structural classes. Changes in all four species usually occur in concert and with remarkably good agreement. A significant cleavage window is not clearly apparent in any case. Thus, these Notch and β -APP cleavages cannot be dissected apart easily since they show the same pharmacol. profile of inhibition. Whether this translates into proportionally reduced Notch signaling in vivo, however, remains to be seen.

IT 209984-57-6


RL: PAC (Pharmacological activity); BIOL (Biological study)

(catalytic site-directed γ -secretase complex inhibitors do not
discriminate pharmacol. between Notch S3 and β -APP cleavages)

RN 209984-57-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:346420 CAPLUS Full-text
 DN 139:159884
 TI Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase
 with
 γ -Secretase Inhibitors
 AU Weihofen, Andreas; Lemberg, Marius K.; Friedmann, Elena; Rueeger,
 Heinrich; Schmitz, Albert; Paganetti, Paolo; Rovelli, Giorgio;
 Martoglio,
 Bruno
 CS Institute of Biochemistry, Swiss Federal Institute of Technology (ETH),
 ETH-Hoenggerberg, Zurich, 8093, Switz.
 SO Journal of Biological Chemistry (2003), 278(19), 16528-16533
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 AB Presenilin is implicated in the pathogenesis of Alzheimer's disease. It
 is thought to constitute the catalytic subunit of the γ -secretase
 complex that catalyzes intramembrane cleavage of β -amyloid precursor
 protein, the last step in the generation of amyloidogenic A β peptides.
 The latter are major constituents of amyloid plaques in the brain of
 Alzheimer's disease patients. Inhibitors of γ -secretase are considered
 potential therapeutics for the treatment of this disease because they
 prevent production of A β peptides. Recently, the authors discovered a
 family of presenilin-type aspartic proteases. The founding member,
 signal peptide peptidase, catalyzes intramembrane cleavage of distinct
 signal peptides in the endoplasmic reticulum membrane of animals. In
 humans, the protease plays a crucial role in the immune system.
 Moreover, it is exploited by the hepatitis C virus for the processing of
 the structural components of the virion and hence is an attractive
 target for anti-infective intervention. Signal peptide peptidase and
 presenilin share identical active site motifs and both catalyze
 intramembrane proteolysis. These common features let the authors
 speculate that γ -secretase inhibitors directed against presenilin may
 also inhibit signal peptide peptidase. Here the authors demonstrate
 that some of the most potent known γ -secretase inhibitors efficiently
 inhibit signal peptide peptidase. However, the authors found compds.
 that showed higher specificity for one or the other protease. The
 authors findings highlight the possibility of developing selective
 inhibitors aimed at reducing A β generation without affecting other
 intramembrane-cleaving aspartic proteases.
 IT 209984-57-6, LY 411575
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (targeting presenilin-type aspartic protease signal peptide peptidase
 with γ -secretase inhibitors in relation to therapeutic uses)
 RN 209984-57-6 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -
 hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:168838 CAPLUS Full-text
DN 138:205345

TI Preparation of cyclic amino acid compounds for inhibiting β -amyloid peptide release and/or its synthesis

IN Audia, James E.; Dressman, Bruce A.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company

SO U.S., 70 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6528505	B1	20030304	US 1999-338180	19990622
	US 6552013	B1	20030422	US 1999-338121	19990622
	US 6569851	B1	20030527	US 1999-338191	19990622
	US 2003162768	A1	20030828	US 2002-317081	20021212
	US 6696438	B2	20040224		
	US 2003149022	A1	20030807	US 2002-326081	20021223
	US 2004106598	A1	20040603	US 2003-392332	20030320
PRAI	US 1998-160067P	P	19980622		
	US 1998-155238P	P	19980930		
	US 1998-150704P	P	19980930		
	US 1998-162757	A	19980930		
	US 1999-338121	A3	19990622		
	US 1999-338180	A3	19990622		
	US 1999-338191	A3	19990622		

OS MARPAT 138:205345


AB Fused azepinone amino acid derivs. R'R''NCHR1CONHCHR2CONH-W and R':NC(:R1)CONHCHR2CONH-W [R1 and R' combine to form a nitrogen-containing optionally-substituted (un)saturated heterocyclyl or heteroaryl group; R'' is H, (un)substituted alkyl or aryl; R2 is (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, or heterocyclyl; W is (un)substituted mono- or dibenzo- or dicyclohexano(hydro)azepin-2-on-3-yl] were prepared for inhibition β -amyloid peptide release and/or its synthesis, and accordingly have utility in treating Alzheimer's disease. Thus, 5(S)-[(N-L-prolyl-L-alanyl)amino]-7-methyl-5,7-dihydro-6H- dibenz[b,d]azepin-6-one was prepared by acylation of 5(S)-amino-7-methyl-5,7- dihydro-6H- dibenz[b,d]azepin-6-one hydrochloride with Boc-Pro-Ala-OH (Boc = tert-butoxycarbonyl), followed by deprotection. Compds. of the invention inhibit β -amyloid peptide production by at least 30% as compared to the control when employed at 10 μ g/mL.

IT 253136-07-1P 253136-11-7P 253136-15-1P
253136-19-5P 253136-20-8P 253136-23-1P
253136-27-5P 253136-32-2P 253136-36-6P
253136-39-9P 253136-41-3P 253136-43-5P
253136-45-7P 253136-52-6P 253136-53-7P
253136-61-7P 253136-65-1P 253136-66-2P
253136-74-2P 253136-75-3P 253194-30-8P
253194-32-0P 253194-34-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release and/or its synthesis)


RN 253136-07-1 CAPLUS
CN L-Alaninamide, L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-11-7 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-15-1 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253136-19-5 CAPLUS
CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-20-8 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-23-1 CAPLUS

CN L-Alaninamide, (4S)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-27-5 CAPLUS


CN L-Alaninamide, (4R)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-41-3 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-43-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-45-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-52-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-53-7 CAPLUS




CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-61-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-, (2S)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 253136-75-3 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-30-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]octahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-32-0 CAPLUS


CN 2-Quinolinecarboxamide, N-[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253194-34-2 CAPLUS
 CN 2-Quinolinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-35-0P
 209984-36-1P 209984-37-2P 209984-38-3P
 209984-39-4P 209984-40-7P 209984-41-8P
 209984-42-9P 209984-43-0P 209984-44-1P
 228877-58-5P 228877-95-0P 253135-42-1P
 253135-43-2P 253136-06-0P 253136-10-6P
 253136-14-0P 253136-18-4P 253136-21-9P
 253136-26-4P 253136-31-1P 253136-34-4P
 253136-38-8P 253136-42-4P 253136-51-5P
 253136-59-3P 253136-63-9P 253194-29-5P
 253194-31-9P 253194-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release and/or its synthesis)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-37-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-39-4 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-43-0 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 228877-58-5 CAPLUS
 CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253135-42-1 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 253135-43-2 CAPLUS
 CN Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-06-0 CAPLUS
 CN L-Alaninamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-10-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-14-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253136-18-4 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 1-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-, 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-21-9 CAPLUS

CN L-Alaninamide, (4S)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-
L-
prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-26-4 CAPLUS

CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-
L-
prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 253136-31-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-
5H-

dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-34-4 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-

dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-38-8 CAPLUS

CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-L-prolyl-N-


(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-42-4 CAPLUS
 CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-51-5 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-3,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-59-3 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-63-9 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 253194-29-5 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 253194-31-9 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-33-1 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:35360 CAPLUS Full-text
 DN 138:90080
 TI Preparation of heterocyclic compounds and their use for inhibiting
 β -amyloid peptide release
 IN Thorsett, Eugene D.; Porter, Warren J.; Nissen, Jeffrey S.; Latimer, Lee
 H.; Audia, James E.; Droste, James
 PA Athena Neurosciences, Inc., USA; Eli Lilly and Company
 SO U.S., 99 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6506782	B1	20030114	US 1998-32019	19980227
	US 2003130188	A1	20030710	US 2002-246558	20020919
PRAI	US 1998-32019	A3	19980227		
OS	MARPAT 138:90080				
GI					



AB Disclosed are modified heterocyclic di- and tripeptide analogs which inhibit β -amyloid peptide release and/or its synthesis and, accordingly, have utility in treating Alzheimer's disease. Compds. of formula $R_1NHCHR_2(CONHCHR_6)_pCONHCHR_5C(:NR_4)R_4$ [R_1 = H or acyl; R_2 , R_5 , R_6 = (un)substituted alk(en)(yn)yl, cycloalkyl, (hetero)aryl, heterocyclyl; p = 0 or 1; R_3 and R_4 combine to form a heterocyclic ring, which may be substituted] are claimed. Also disclosed are pharmaceutical compns. comprising a compound which inhibits β -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compns. Title compds., e.g. I, were prepared in a multistep synthesis and inhibited β -amyloid peptide production by at least 30% as compared to control.

IT **209984-35-0P 209984-36-1P 209984-39-4P**
209984-40-7P 209984-43-0P 209984-44-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic compds. and their use for inhibiting β -amyloid peptide release)
 RN 209984-35-0 CAPLUS
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-36-1 CAPLUS

CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-39-4 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-40-7 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 209984-33-8P 209984-34-9P 209984-37-2P
 209984-38-3P 209984-41-8P 209984-42-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT (Reactant or reagent)
 (preparation of heterocyclic compds. and their use for inhibiting
 β-amyloid peptide release)
 RN 209984-33-8 CAPLUS
 CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT, 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:332680 CAPLUS Full-text
 DN 136:340709
 TI Preparation and use of hydroxyalkanoyl aminolactams and related
 structures as inhibitors of β -amyloid protein production
 IN Olson, Richard E.; Liu, Hong; Thompson, Lorin A., III
 PA USA
 SO U.S. Pat. Appl. Publ., 89 pp., Cont.-in-part of U. S. Ser. No. 661,008.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002052360	A1	20020502	US 2001-805645	20010314
	US 6503902	B2	20030107		
	US 2003166636	A1	20030904	US 2002-287117	20021104
PRAI	US 1999-153511P	P	19990913		
	US 2000-224388P	P	20000809		
	US 2000-661008	A2	20000913		
	US 2001-805645	A3	20010314		
OS	MARPAT 136:340709				
GI					



AB Title compds. I [wherein Q = Q1, alkyl-OQ1, alkyl-S(O)O-2Q1, or alkyl-NR2OQ1; Q1 = substituted alkyl, alkenyl, alkynyl, carbocyclyl, aryl, or heterocyclyl; R20 = H, OH, alkyl, Ph, CH2Ph, or (CH2)2Ph; R2 = H, Me, Et, Pr, or Bu; R3 = H, alkyl, alkanoyl, alkylthioyl, or carboxyamido; or R2(OR3) = CO or C:NOH; R5 = H, OH, OR14, substituted (cyclo)alkyl, alkoxy, alkenyl, alkynyl, carbocyclyl, aryl, or heterocyclyl; R14 = H, Ph, CH2Ph, or (alkoxy)alkyl; R5a = H, alkyl, or alkenyl; or R5R5a = (un)substituted (benzo-fused)carbocycle; R6 = H or alkyl; W = (CR8R8a)p; R8 and R8a = independently H, F, (cyclo)alkyl, alkenyl, or alkynyl; p = 0-4; X = a bond or (un)substituted aryl, cycloalkyl, or heterocyclyl; Y = a bond or (CR9R9a)tV(CR9R9a)u; R9 and R9a = independently H, F, or (cyclo)alkyl; t = 0-3; u = 0-3; Z = H or (un)substituted alkyl, alkenyl, alkynyl, aryl, carbocyclyl, or heterocyclyl; n = 1-3; addnl. the lactam may be saturated, substituted, contain heteroatom(s), or bear two adjacent substituents which may combine to form a carbocycle-fused radical, benzo-fused radical, etc.] were prepared as β -amyloid protein (A β) production inhibitors, thereby acting to prevent the formation of neurol. deposits of amyloid protein. One hundred seventy-five examples were provided. For example, carbodiimide coupling of 2(R)-

cyclopentylmethyl-3(S)-hydroxy-5- phenylpentanoic acid with 3-amino-1-methyl-5-phenyl-2,3-dihydro-1H-1,4- benzodiazepin-2-one•TsOH using 1-hydroxybenzotriazole•H₂O and TEA in CH₂Cl₂ afforded II (25%). In an immunopptn. assay using N9 cells, characterized for expression of exogenous amyloid precursor protein (APP), I inhibited the production of β -amyloid protein (A β) with an IC₅₀ of Ki < 100 μ M. I are useful in the treatment of neurol. disorders related to A β production, such as Alzheimer's disease and Down's Syndrome.

IT 418812-91-6P 418812-92-7P 418812-98-3P
418813-01-1P 418813-63-5P 418813-64-6P
418813-65-7P 418813-68-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(β -amyloid inhibitor; preparation and use of hydroxyalkanoyl aminolactams and related structures as inhibitors of β -amyloid protein production for treatment of neurol. disorders, such as

Alzheimer's


disease and Down's Syndrome)

RN 418812-91-6 CAPLUS

CN Cyclopropanepropanamide, N-[5-[2-(diethylamino)ethyl]-6,7-dihydro-6-oxo-5H-

dibenz[b,d]azepin-7-yl]- α -[(1S)-1-hydroxypentyl]-, (α R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 418812-92-7 CAPLUS

CN Cyclopropanepropanamide, N-[6,7-dihydro-5-(3-hydroxypropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]- α -[(1S)-1-hydroxypentyl]-, (α R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 418812-98-3 CAPLUS

CN Cyclopropanepropanamide, N-(5-butyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-

7-yl)-α-[(1S)-1-hydroxypentyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418813-01-1 CAPLUS

CN Cyclopropanepropanamide, N-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-α-[(1S)-1-hydroxypentyl]-, (αR)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 418813-63-5 CAPLUS

CN Cyclopropanepropanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-α-[(1S)-1-hydroxypentyl]-, (αR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 418813-64-6 CAPLUS

CN Cyclopropanepropanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-α-[(1S)-1-hydroxyhexyl]-, (αR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 418813-65-7 CAPLUS

CN 2-Furanpentanamide, α-(cyclopropylmethyl)-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-β-hydroxy-, (αR,βS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 418813-68-0 CAPLUS

CN Cyclopropanepropanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-


dibenz[b,d]azepin-7-yl)- α -[(1S)-1-hydroxyheptyl]-, (α R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:886081 CAPLUS Full-text
 DN 136:20092
 TI Preparation of N-oxodiazepinyl[carbamoylcycloalk(en)yl]alkanoamides as
 γ-secretase inhibitors
 IN Olson, Richard E.
 PA Dupont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 254 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001092235	A1	20011206	WO 2001-US17865	20010601
	W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IN, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	BR 2001006717	A	20020416	BR 2001-6717	20010601
	US 2002137737	A1	20020926	US 2001-871840	20010601
	US 6509333	B2	20030121		
	EP 1268450	A1	20030102	EP 2001-944228	20010601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
	NO 2002000403	A	20020305	NO 2002-403	20020125
	US 2003119815	A1	20030626	US 2002-287099	20021104
PRAI	US 2000-208536P	P	20000601		
	US 2001-871840	A3	20010601		
	WO 2001-US17865	W	20010601		
OS	MARPAT 136:20092				
GI					



AB RZZ1Z2NR7COCHR8NR6COCR5R5aCR3R3aCONR1R2 [I; R = H, alkyl, aryl, etc.; R1 = H, alkyl, Ph, etc.; R2 = H, OH, alkyl, alkoxy, Ph, etc.; R3R3a = atoms to complete a carbocyclic moiety (sic), heterocyclylidene, etc.; R5 = alkyl, alkoxy, heterocyclyl, aryl, etc.; R5a = h or alk(en)yl; R6 = H, alkyl, carbocycle (sic), aryl, etc.; R7R8 = atoms to complete a 6- to 8-membered lactam; Z = bond or (un)substituted (heteroatom-interrupted) (oxo)alkylene; Z1 = bond, cycloalkylene, arylene, etc.; Z2 =

bond or (un)substituted alkylene] were prepared Thus, (R)-Me₃CO₂CC(CH₂CH:CH₂)₂CH(CH₂CHMe₂)CO₂H was amidated by 3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one and the product converted in 3 steps to title compound II. Data for biol. activity of I were given.

IT 378246-04-9P 378246-20-9P 378246-23-2P
378246-26-5P 378246-56-1P 378246-62-9P
378246-64-1P 378246-66-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-oxodiazepinyl[carbamoylcycloalk(en)yl]alkanoamides as
γ-secretase inhibitors)

RN 378246-04-9 CAPLUS

CN Cyclohexaneacetamide, 1-(aminocarbonyl)-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-α-(2-methylpropyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378246-20-9 CAPLUS

CN 3-Cyclopentene-1-acetamide, 1-(aminocarbonyl)-α-(cyclopropylmethyl)-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378246-23-2 CAPLUS

CN 3-Cyclopentene-1-acetamide, 1-(aminocarbonyl)-N-[(7R)-6,7-dihydro-5-

methyl-

6-oxo-5H-dibenz[b,d]azepin-7-yl]- α -(2-methylpropyl)-,
(α S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 378246-26-5 CAPLUS


CN Cyclopentaneacetamide, 1-(aminocarbonyl)-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- α -(2-methylpropyl)-, (α S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 378246-56-1 CAPLUS

CN Cyclohexaneacetamide, 1-(aminocarbonyl)-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- α -(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 378246-62-9 CAPLUS


CN 3-Cyclopentene-1-acetamide, 1-(aminocarbonyl)- α -(cyclopropylmethyl)-
N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA
INDEX
NAME)



RN 378246-64-1 CAPLUS
CN 3-Cyclopentene-1-acetamide, 1-(aminocarbonyl)-N-(6,7-dihydro-5-methyl-6-
oxo-5H-dibenz[b,d]azepin-7-yl)- α -(2-methylpropyl)- (9CI) (CA INDEX
NAME)




RN 378246-66-3 CAPLUS
CN Cyclopentaneacetamide, 1-(aminocarbonyl)-N-(6,7-dihydro-5-methyl-6-oxo-
5H-
dibenz[b,d]azepin-7-yl)- α -(2-methylpropyl)- (9CI) (CA INDEX NAME)



IT 378246-94-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT
(Reactant or reagent)
(preparation of N-oxodiazepinyl[carbamoylcycloalk(en)yl]alkanoamides
as

γ-secretase inhibitors)
RN 378246-94-7 CAPLUS
CN 3-Cyclopentene-1-carboxylic acid, 1-[(1R)-1-(cyclopropylmethyl)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L4 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:762977 CAPLUS Full-text
 DN 135:303916
 TI Preparation of substituted lactams as inhibitors of a β protein
 production
 IN Han, Wei; Liu, Hong; Olson, Richard E.; Yang, Michael G.
 PA DuPont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 201 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077086	A1	20011018	WO 2001-US11714	20010411
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002025955	A1	20020228	US 2001-832455	20010411
	US 6632812	B2	20031014		
	EP 1289966	A1	20030312	EP 2001-930471	20010411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004500419	T2	20040108	JP 2001-575561	20010411
PRAI	US 2000-196549P	P	20000411		
	WO 2001-US11714	W	20010411		
OS	MARPAT 135:303916				
GI					



L4 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:359966 CAPLUS Full-text
 DN 134:367191
 TI Preparation of β -amino acid compounds useful for inhibiting
 β -amyloid peptide release and/or its synthesis
 IN Audia, James Edmund; Porter, Warren Jaye; Scott, William Leonard; Stack,
 Douglas Richard; Thompson, Richard Craig
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034571	A1	20010517	WO 2000-US26278	20001026
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LÜ, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1230220	A1	20020814	EP 2000-978213	20001026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003513958	T2	20030415	JP 2001-536519	20001026
PRAI	US 1999-164399P	P	19991109		
	WO 2000-US26278	W	20001026		

OS MARPAT 134:367191

AB β -Amino acid-containing compds. R1-Z-CONHCHR2CHR3CONH-W [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl; R2, R3 = H, alkyl, cycloalkyl, aryl; Z is -CX'X''-, where X', X'' = H, OH, F or X'X'' = oxo; W is benzo- or dibenzoazepinone or 1,4-diazepinone, benzo-1,4-oxazepinone or -thiazepinone groups which may be substituted] were prepared for inhibiting β -amyloid peptide release and/or its synthesis and are useful in treating Alzheimer's disease and cognition enhancement. Thus, 5-(S)-[[N-[(S)-2-hydroxy-3-methylbutyryl]-(R- or S)- β -methyl- β -alaninyl]amino]-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one isomers were prepared via coupling of (R/S)-N-Boc- β -methyl- β -alanine with 5-(S)-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride (preparation given). Compds. of the invention were assayed for their ability to inhibit β -amyloid production (formulations described).

IT 339545-71-0P 339545-72-1P 339545-73-2P
 339545-74-3P 339545-77-6P 339545-78-7P
 339545-79-8P 339545-80-1P 339545-81-2P
 339545-82-3P 339563-89-2P 339563-90-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of β -amino acid compds. useful for inhibiting
 β -amyloid peptide release and/or its synthesis)

RN 339545-71-0 CAPLUS

CN Butanamide, N-[(1R)-3-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-3-oxopropyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339545-72-1 CAPLUS

CN Butanamide, N-[(1S)-3-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-3-oxopropyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339545-73-2 CAPLUS

CN Benzeneacetamide, N-[(1R)-3-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-3-oxopropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339545-74-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-3-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-3-oxopropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339545-77-6 CAPLUS

CN Butanamide, N-[(2S)-3-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-methyl-3-oxopropyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339545-78-7 CAPLUS


CN Benzeneacetamide, N-[(2R)-3-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-methyl-3-oxopropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 339545-79-8 CAPLUS

CN Benzeneacetamide, N-[3-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-3-oxopropyl]-3,5-difluoro- (9CI) (CA INDEX NAME)




RN 339545-80-1 CAPLUS

CN 2-Thiopheneacetamide, N-[3-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 339545-81-2 CAPLUS

CN Butanamide, N-[3-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-3-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 339545-82-3 CAPLUS


CN Benzeneacetamide, N-[3-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 339563-89-2 CAPLUS

CN Benzeneacetamide, N-[(2S)-3-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-methyl-3-oxopropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339563-90-5 CAPLUS

CN Butanamide, N-[(2R)-3-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-methyl-3-oxopropyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 339545-70-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of β -amino acid compds. useful for inhibiting
 β -amyloid peptide release and/or its synthesis)

RN 339545-70-9 CAPLUS

CN Butanamide, 3-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 339545-69-6P 339545-75-4P 339545-76-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of β -amino acid compds. useful for inhibiting
 β -amyloid peptide release and/or its synthesis)

RN 339545-69-6 CAPLUS

CN Carbamic acid, [3-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-
yl]amino]-1-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX
NAME)


Absolute stereochemistry.



RN 339545-75-4 CAPLUS

CN Carbamic acid, [3-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 339545-76-5 CAPLUS

CN Propanamide, 3-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:208247 CAPLUS Full-text
 DN 134:252364
 TI Preparation and use of hydroxyalkanoyl aminolactams and related
 structures as inhibitors of A β protein production
 IN Olson, Richard Eric; Liu, Hong; Thompson, Lorin Andrew, III
 PA Du Pont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 221 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019797	A2	20010322	WO 2000-US24967	20000913
	WO 2001019797	A3	20020411		
	W:	AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	EP 1212306	A2	20020612	EP 2000-963374	20000913
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
	BR 2000014269	A	20020702	BR 2000-14269	20000913
PRAI	US 1999-153511P	P	19990913		
	US 2000-224388P	P	20000809		
	WO 2000-US24967	W	20000913		
OS	MARPAT 134:252364				
GI					



I



II


AB Compds. of formula I are claimed [wherein; Q is Q1, alkyl-(O or S(O)O-2 or N)-Q1; Q1 is substituted alk(en)(yn)yl, carbocycle, aryl or heterocycle; R2 is H, Me, Et, Pr or Bu; R3 is H, (CO)(CS)alkyl, alkylamine or amide; or R2, OR3 taken together form oxo or hydroximino; R5 is H, OH, substituted alk(ox)(en)(yn)yl, substituted carbocycle or heterocycle, etc.; R5a is H, alk(en)yl, or R5, R5a together form a 3-7 membered (substituted) (benzo-fused)carbocycle; R6 is H or alkyl, W is (substituted) alkyl; X is a bond, substituted (aryl or cycloalkyl or heterocycle); Y is a bond or divalent carbo and/or heteroat. bridge; Z is H, (substituted) alk(en)(yn)yl, (substituted) aryl or carbo(hetero)cycle; n is 1, 2 or 3; addnl. the lactam may be saturated, substituted, or contain addnl. heteroatom(s) and the lactam may bear two

adjacent substituents which may combine to form a carbocycle-fused radical, benzo-fused radical, etc.]. Synthesis of II was accomplished by carbodiimide coupling of 2(R)-cyclopentylmethyl-3(S)-hydroxyl-5-phenylpentanoic acid with the corresponding 3-aminobenzodiazepine. One hundred thirty five examples were provided. Compds. I inhibit the production of β -amyloid protein ($A\beta$) with an IC_{50} or $K_i < 100 \mu M$ in an immunopptn. assay using N9 cells, characterized for expression of exogenous amyloid precursor protein (APP). Claimed uses for I are treatment of neurol. disorders related to $A\beta$ production such as Alzheimer's disease and Down's Syndrome.

IT 330840-82-9P 330840-83-0P 330840-84-1P
330840-85-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of hydroxyalkanoyl aminolactams and derivs. as inhibitors of $A\beta$ protein production)
RN 330840-82-9 CAPLUS
CN Cyclopropanepropanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- α -[(1S)-1-hydroxypentyl]-, (α R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 330840-83-0 CAPLUS
CN Cyclopropanepropanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- α -[(1S)-1-hydroxyhexyl]-, (α R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 330840-84-1 CAPLUS
 CN Cyclopropanepropanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- α -[(1S)-1-hydroxyheptyl]-, (α R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.





RN 330840-85-2 CAPLUS
 CN 2-Furanpentanamide, α -(cyclopropylmethyl)-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- β -hydroxy-, (α R, β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:456838 CAPLUS Full-text
 DN 133:89552
 TI Succinoylaminobenzodiazepines as inhibitors of A β protein production
 IN Olson, Richard E.
 PA Du Pont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 256 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038618	A2	20000706	WO 1999-US30815	19991223
	WO 2000038618	A3	20030403		
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 2000020592	A5	20000731	AU 2000-20592	19991223
	BR 9917082	A	20011106	BR 1999-17082	19991223
	EP 1313426	A2	20030528	EP 1999-964322	19991223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	JP 2003523932	T2	20030812	JP 2000-590572	19991223
	NO 2001002984	A	20010615	NO 2001-2984	20010615
PRAI	US 1998-113588P	P	19981224		
	WO 1999-US30815	W	19991223		
OS	MARPAT 133:89552				
GI					



AB Succinoylaminobenzodiazepines I [R = (un)substituted NH₂; R₁ = (un)substituted alkyl; R₂, R₄ = H, OH, alkyl, alkoxy, alkenyl, alkenyloxy; R₃ = H, (un)substituted OH, alkyl, alkoxy, alkenyl, alkynyl,

carbocyclic aryl, heterocyclic; R5, R6 = H, (un)substituted alkyl, carbocyclic, aryl; R7 = (un)substituted ph, pyridyl] were prepared I inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A β -peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein and are useful in the treatment of neurol. disorders related to β -amyloid production such as Alzheimer's disease and Down's Syndrome. Thus, the title compound II was prepared by treating (2R,3S)-Me3CO2CCH(CH2CH:CH2)CH(CH2CHMe2)CO2H with the aminobenzodiazepine, ester hydrolysis, and amidation.

IT 280568-92-5P 280568-93-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of succinoylaminobenzodiazepines as inhibitors of A β -protein production)

RN 280568-92-5 CAPLUS

CN Hexanoic acid, 3-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-5-methyl-2-(2-propenyl)-, 1,1-dimethylethyl ester, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-93-6 CAPLUS

CN Hexanoic acid, 3-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-5-methyl-2-(2-propenyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **280568-94-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of succinoylaminobenzodiazepines as inhibitors of $A\beta$ -protein production)

RN 280568-94-7 CAPLUS

CN Butanediamide, N1-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-

(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:227868 CAPLUS Full-text
 DN 132:262407
 TI Biological reagents and methods for determining the mechanism in the
 generation of β -amyloid peptide
 IN Audia, James E.; Hyslop, Paul A.; Nissen, Jeffrey S.; Thompson, Richard
 C.; Tung, Jay S.; Tanner, Laura I.
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000019210	A2	20000406	WO 1999-US22684	19990929
	WO 2000019210	A3	20010118		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9962780	A1	20000417	AU 1999-62780	19990929
	EP 1131634	A2	20010912	EP 1999-950039	19990929
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	US 6486350	B1	20021126	US 1999-408283	19990929
	JP 2003524601	T2	20030819	JP 2000-572665	19990929
	US 2003069445	A1	20030410	US 2002-217459	20020814
PRAI	US 1998-160082P	P	19980930		
	US 1999-408283	A3	19990929		
	WO 1999-US22684	W	19990929		

OS MARPAT 132:262407

AB Biol. reagents are described which comprise compds. that inhibit β -amyloid peptide release and/or its synthesis. These compds. have utility in determining the cellular mechanism involved in the generation of β -amyloid peptide. The synthesis of these compds. are described extensively.

IT **209984-57-6P**


RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(synthesis of biol. reagents and methods for determining mechanism in generation of β -amyloid peptide)

RN 209984-57-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 209984-58-7P 209984-68-9P

RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)(synthesis of biol. reagents and methods for determining mechanism in generation of β -amyloid peptide)

RN 209984-58-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 209984-68-9 CAPLUS

CN Butanamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 209984-35-0 253324-50-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of biol. reagents and methods for determining mechanism in generation of β -amyloid peptide)

RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253324-50-4 CAPLUS



CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:117029 CAPLUS Full-text
 DN 132:166134
 TI Preparation of succinoylaminoazepinones and related compounds as
 inhibitors of A β -peptide production.
 IN Olson, Richard E.; Maduskuie, Thomas P.; Thomas, Lorin Andrew
 PA Du Pont Pharmaceuticals Co., USA
 SO PCT Int. Appl., 315 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000007995	A1	20000217	WO 1999-US17717	19990807
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	HR 990246	A1	20000630	HR 1999-990246	19990806
	CA 2338944	AA	20000217	CA 1999-2338944	19990807
	AU 9953378	A1	20000228	AU 1999-53378	19990807
	AU 756830	B2	20030123		
	EP 1102752	A1	20010530	EP 1999-939010	19990807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100377	T2	20010621	TR 2001-200100377	19990807
	BR 9912969	A	20010925	BR 1999-12969	19990807
	NZ 509241	A	20030829	NZ 1999-509241	19990807
	JP 2003526603	T2	20030909	JP 2000-563629	19990807
	US 2003134841	A1	20030717	US 2002-285776	20021101
PRAI	US 1998-95698P	P	19980807		
	US 1998-113558P	P	19981224		
	US 1999-120227P	P	19990215		
	US 1999-370089	A	19990806		
	US 1998-113588P	P	19981224		
	WO 1999-US17717	W	19990807		
	US 2000-506360	A3	20000217		
OS	MARPAT 132:166134				
GI					



AB Title compds. [I; Q = OR1, NR1R2; R1 = H, (substituted) alkyl, alkenyl, carbocyclyl, aryl, heterocyclyl; R2 = H, NH2, OH, alkyl, alkoxy, PhO, PhCH2O, carbocyclyl, aryl, heterocyclyl; R3 = (CR7R7a)nR4, etc.; n = 0-

3; R3a = H, OH, alkyl, alkoxy, alkenyloxy; R4 = H, OH, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl; R5 = H, OR14, (substituted) alkyl, alkoxy, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl; R14 = H, Ph, PhCH2, alkyl, alkoxyalkyl; R5a = H, OH, alkyl, alkoxy, alkenyl, alkenyloxy; R6 = H, (substituted) alkyl, carbocyclyl, aryl; R7, R7a = H, OH, Cl, F, Br, iodo, cyano, NO2, CF3, alkyl; W = (CR8R8a)p; p = 0-4; R8, R8a = H, F, alkyl, alkenyl, alkynyl, cycloalkyl; X = bond, (substituted) aryl, carbocyclyl, heterocyclyl; Y = bond, (CR9R9a)tV(CR9R9a)u; t, u = 0-3; R9, R9a = H, F, alkyl, cycloalkyl; V = bond, CO, O, S, SO, SO2, imino, etc.; Z = (substituted) alkyl, aryl, carbocyclyl, heterocyclyl; B = atoms to form an (unsatd.) (substituted) (heteroatom-containing) lactam ring], were prepared which inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A β -peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein. Thus, title compound (II) was prepared in several steps starting with L- α -amino- ϵ -caprolactam. I inhibited A β production with IC50<100 μ M.

IT 258867-32-2P 258867-33-3P 258867-34-4P
 258867-35-5P 258867-36-6P 258867-37-7P
 258867-38-8P 258867-39-9P 258867-40-2P
 258867-41-3P 258867-42-4P 258867-43-5P
 258867-44-6P 258867-45-7P 258867-47-9P
 258867-49-1P 258867-51-5P 258867-53-7P
 258867-55-9P 258867-57-1P 258867-59-3P
 258867-61-7P 258867-63-9P 258867-64-0P
 258867-65-1P 258867-66-2P 258867-67-3P
 258867-68-4P 258867-69-5P 258867-70-8P
 258867-71-9P 258867-72-0P 258867-73-1P
 258867-74-2P 258867-75-3P 258867-76-4P
 258867-77-5P 258867-78-6P 258867-79-7P
 258867-80-0P 258867-81-1P 258867-82-2P
 258867-83-3P 258867-84-4P 258867-85-5P
 258867-86-6P 258867-87-7P 258867-88-8P
 258867-89-9P 258867-90-2P 258867-91-3P
 258867-92-4P 258867-93-5P 258867-94-6P
 258867-95-7P 258867-96-8P 258867-97-9P
 258867-98-0P 258867-99-1P 258868-00-7P
 258868-01-8P 258868-02-9P 258868-03-0P
 258868-04-1P 258868-05-2P 258868-06-3P
 258868-07-4P 258868-08-5P 258868-09-6P
 258868-10-9P 258868-11-0P 258868-12-1P
 258868-13-2P 258868-14-3P 258868-15-4P
 258868-16-5P 258868-17-6P 258868-18-7P
 258868-19-8P 258868-20-1P 258868-21-2P
 258868-22-3P 258868-23-4P 258868-24-5P
 258868-25-6P 258868-26-7P 258868-27-8P
 258868-28-9P 258868-29-0P 258868-30-3P
 258868-32-5P 258868-34-7P 258868-36-9P
 258868-38-1P 258868-40-5P 258868-42-7P
 258868-43-8P 258868-44-9P 258868-46-1P
 258868-47-2P 258868-49-4P 258868-50-7P
 258868-51-8P 258868-52-9P 258868-53-0P
 258868-54-1P 258868-55-2P 258868-56-3P
 258868-57-4P 258868-58-5P 258868-59-6P
 258868-60-9P 258868-61-0P 258868-62-1P
 258868-63-2P 258868-64-3P 258868-65-4P

258868-66-5P 258868-67-6P 258868-68-7P
258868-69-8P 258868-70-1P 258868-71-2P
258868-72-3P 258868-73-4P 258868-74-5P
258868-75-6P 258868-76-7P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of succinoylaminoazepinones and related compds. as
inhibitors

of A β -peptide production)


RN 258867-32-2 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-
dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA

INDEX NAME)


Absolute stereochemistry.



RN 258867-33-3 CAPLUS


CN Butanediamide, N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-
yl)methyl]-
6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-34-4 CAPLUS
 CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-35-5 CAPLUS
 CN Butanediamide, N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258867-36-6 CAPLUS
 CN Butanediamide, N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-37-7 CAPLUS

CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-

dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-38-8 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-
dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA
INDEX NAME)


Absolute stereochemistry.



RN 258867-39-9 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-40-2 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-41-3 CAPLUS


CN Butanediamide, N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258867-43-5 CAPLUS
CN Butanediarnide, N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-44-6 CAPLUS

CN Butanediamide, N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-45-7 CAPLUS

CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-47-9 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-49-1 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-51-5 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-53-7 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-55-9 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-5-[[4'-methyl[1,1'-biphenyl]-3-yl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-57-1 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-59-3 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-61-7 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-63-9 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-64-0 CAPLUS


CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-65-1 CAPLUS
 CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-66-2 CAPLUS
 CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258867-67-3 CAPLUS
 CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-68-4 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-69-5 CAPLUS

CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-70-8 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-71-9 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-72-0 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-73-1 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-74-2 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-75-3 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[4'-methyl[1,1'-biphenyl]-3-yl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-76-4 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-

3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-,

(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-77-5 CAPLUS

CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-

dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-78-6 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-79-7 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-80-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-81-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-82-2 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-83-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-84-4 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-85-5 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-86-6 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(cyclopropylmethyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-87-7 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-88-8 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-89-9 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-90-2 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-91-3 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-92-4 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-93-5 CAPLUS

CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-94-6 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-95-7 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-96-8 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-97-9 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-98-0 CAPLUS


CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-99-1 CAPLUS
 CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-00-7 CAPLUS
 CN Butanediamide, 2-(cyclobutylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-01-8 CAPLUS
 CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-02-9 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-03-0 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-04-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-05-2 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-06-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-07-4 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-08-5 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-09-6 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-

yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-10-9 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(cyclobutylmethyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258868-11-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-12-1 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258868-13-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-14-3 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-15-4 CAPLUS


CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-16-5 CAPLUS
 CN Butanediamide, 2-(cyclopentylmethyl)-N1-[5-[(2',4'-dimethylbiphenyl-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-,
 (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-17-6 CAPLUS
 CN Butanediamide, N1-[5-[(3'-chloro-4'-fluorobiphenyl-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-propyl-,
 (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-18-7 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258868-19-8 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-20-1 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-21-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-22-3 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-23-4 CAPLUS


CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[4'-methyl[1,1'-biphenyl]-3-yl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-24-5 CAPLUS
 CN Butanediamide, 2-(cyclopentylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-25-6 CAPLUS
 CN Butanediamide, N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-26-7 CAPLUS
 CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-27-8 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-28-9 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[3-(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-29-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-30-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-32-5 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-34-7 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-36-9 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-38-1 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-40-5 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-42-7 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-43-8 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-(2-phenylethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA
INDEX NAME)

Absolute stereochemistry.




RN 258868-44-9 CAPLUS

CN Butanediamide, N1-[5-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)


(CA
INDEX NAME)

Absolute stereochemistry.




RN 258868-46-1 CAPLUS
 CN Butanediamide, N1-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-47-2 CAPLUS
 CN Butanediamide, N1-[5-(cyclobutylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-49-4 CAPLUS

CN Butanediamide, N1-[5-(cyclopentylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA
INDEX NAME)

Absolute stereochemistry.




RN 258868-50-7 CAPLUS

CN Butanediamide, N1-[5-(cyclohexylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA
INDEX NAME)

Absolute stereochemistry.




RN 258868-51-8 CAPLUS

CN Butanediamide, N1-[5-(2-cyclopropylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.




RN 258868-52-9 CAPLUS

CN Butanediamide, N1-[5-(2-cyclobutylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)

(CA


INDEX NAME)

Absolute stereochemistry.




RN 258868-53-0 CAPLUS
 CN Butanediamide, N1-[5-(2-cyclopentylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-54-1 CAPLUS
 CN Butanediamide, N1-[5-(2-cyclohexylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-55-2 CAPLUS
 CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-56-3 CAPLUS
 CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-(2-phenylethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-57-4 CAPLUS
 CN Butanediamide, N1-[5-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-58-5 CAPLUS

CN Butanediamide, N1-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-59-6 CAPLUS

CN Butanediamide, N1-[5-(cyclobutylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-60-9 CAPLUS

CN Butanediamide, N1-[5-(cyclopentylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-61-0 CAPLUS

CN Butanediamide, N1-[5-(cyclohexylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-62-1 CAPLUS

CN Butanediamide, N1-[5-(2-cyclopropylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-63-2 CAPLUS

CN Butanediamide, N1-[5-(2-cyclobutylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-64-3 CAPLUS

CN Butanediamide, N1-[5-(2-cyclopentylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-65-4 CAPLUS

CN Butanediamide, N1-[5-(2-cyclohexylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-66-5 CAPLUS
 CN Butanediamide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-67-6 CAPLUS
 CN Butanediamide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-(2-phenylethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-68-7 CAPLUS
 CN Butanediamide, 3-butyl-N1-[5-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-69-8 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-70-1 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(cyclobutylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-71-2 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(cyclopentylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-72-3 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(cyclohexylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-73-4 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(2-cyclopropylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-74-5 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(2-cyclobutylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-75-6 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(2-cyclopentylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-76-7 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-(2-cyclohexylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:819353 CAPLUS Full-text
DN 132:64534

TI Preparation of cyclic amino acid compounds for inhibiting β -amyloid peptide release and/or its synthesis

IN Thompson, Richard C.; Wilkie, Stephen; Stack, Douglas R.; Vanmeter, Eldon E.; Shi, Qing; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Henry, Steven S.; Mcdaniel, Stacey L.; Stucky, Russell D.; Porter, Warren J.

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company; et al.

SO PCT Int. Appl., 714 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9967221	A1	19991229	WO 1999-US14193	19990622
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325389	AA	19991229	CA 1999-2325389	19990622
	AU 9947101	A1	20000110	AU 1999-47101	19990622
	EP 1089980	A1	20010411	EP 1999-930594	19990622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518483	T2	20020625	JP 2000-555875	19990622
PRAI	US 1998-102507	A2	19980622		
	WO 1999-US14193	W	19990622		
OS	MARPAT 132:64534				
AB	Cyclic compds., e.g., R1R15'NC(Q)NR15(Y)n(CH)pC(X)W [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, aryl, heterocyclyl, heteroaryl; R15 = H, alkyl, substituted alkyl, aryl, heteroaryl, heterocyclyl; R15' = H, OH, alkyl, substituted alkyl, heterocyclyl, heteroaryl; W together with (CH)pC(X) forms an (un)substituted cycloalkyl or cycloalkenyl, heterocyclyl, which are optionally fused to form a bi- or multi-fused ring systems; X = oxo, thioxo, hydroxyl, thiol, or hydro (H,H); Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; p = 0 or 1], were prepared for inhibition of β -amyloid peptide release and/or its synthesis. Thus, (S)-3-[[N-(2-thiophenecarbonyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prepared via acylation of (S)-3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 2-thiophenecarboxylic acid. Compds. of the invention inhibit β -amyloid peptide production by at least 30% as compared to the control.				
IT	209994-06-9P 209994-34-3P 253161-95-4P				
	253322-71-3P 253322-72-4P 253323-63-6P				
	253323-64-7P 253323-65-8P 253323-67-0P				
	253323-68-1P 253323-69-2P 253323-70-5P				


253323-71-6P 253323-72-7P 253323-73-8P
 253323-74-9P 253323-76-1P 253323-77-2P
 253323-78-3P 253323-79-4P 253323-80-7P
 253323-81-8P 253323-82-9P 253323-83-0P
 253323-84-1P 253323-85-2P 253323-86-3P
 253323-87-4P 253323-88-5P 253323-90-9P
 253323-91-0P 253323-92-1P 253323-93-2P
 253323-94-3P 253323-95-4P 253323-96-5P
 253323-97-6P 253323-98-7P 253323-99-8P
 253324-00-4P 253324-01-5P 253324-02-6P
 253324-03-7P 253324-04-8P 253324-05-9P
 253324-06-0P 253324-07-1P 253324-08-2P
 253324-09-3P 253324-10-6P 253324-11-7P
 253324-12-8P 253324-13-9P 253324-14-0P
 253324-15-1P 253324-16-2P 253324-17-3P
 253324-18-4P 253324-19-5P 253324-20-8P
 253324-21-9P 253324-22-0P 253324-23-1P
 253324-24-2P 253324-31-1P 253324-32-2P
 253324-34-4P 253324-35-5P 253324-36-6P
 253324-38-8P 253324-40-2P 253324-41-3P
 253324-42-4P 253324-43-5P 253324-50-4P
 253324-51-5P 253324-52-6P 253324-53-7P
 253324-68-4P 253324-73-1P 253324-74-2P
 253324-82-2P 253324-83-3P 253324-84-4P
 253324-85-5P 253328-98-2P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses) (preparation of cyclic amino acid compds. for inhibiting β -amyloid
 peptide release)

RN 209994-06-9 CAPLUS

CN L-Alaninamide, N-acetyl-N-phenylglycyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-34-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-phenoxy- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 253161-95-4 CAPLUS

CN L-Alaninamide, N-(4-methylpentyl)-L-valyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253322-71-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253322-72-4 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-63-6 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-64-7 CAPLUS


CN Hexanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

Absolute stereochemistry.




CN L-Alaninamide, glycyl-3,5-difluoro- α -hydroxybenzeneacetyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- α -phenyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253323-68-1 CAPLUS

CN Propanamide, 2-(acetylamino)-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-69-2 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 253323-70-5 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-71-6 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-72-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 253323-73-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy-α-methyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-74-9 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy-α-methyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-76-1 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(phenylsulfonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-77-2 CAPLUS


CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[3-fluorophenyl)sulfonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-78-3 CAPLUS
 CN Propanamide, 2-[[(butylamino) carbonyl] amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-79-4 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[(phenylmethyl)amino] carbonyl] amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-80-7 CAPLUS
 CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[[(phenylmethyl)sulfonyl] amino] carbonyl] amino]-, (2S)- (9CI) (CA INDEX NAME)
 INDEX NAME)

Absolute stereochemistry.




RN 253323-81-8 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(ethylamino)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-82-9 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(2-phenylethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-83-0 CAPLUS

CN L-Valinamide, 2-(3,5-difluorophenyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-84-1 CAPLUS


CN L-Valinamide, 2-(3,5-difluorophenyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-85-2 CAPLUS
 CN Propanamide, 2-[(butylsulfonyl)amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-86-3 CAPLUS
 CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(octylsulfonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-87-4 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[2-(2-thienyl)ethyl]amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-88-5 CAPLUS
 CN L-Alaninamide, 2-(3,5-difluorophenyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-90-9 CAPLUS
 CN Propanamide, N-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[[(2-hydroxy-2-phenylethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-91-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(hexylamino)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-92-1 CAPLUS

CN Propanamide, 2-[[[(cyclohexylamino)carbonyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-93-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(1-methylethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-94-3 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-95-4 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylamino)carbonyl]amino]-, (2S)- (9CI)
(CA


INDEX NAME)

Absolute stereochemistry.




RN 253323-96-5 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[(2-methylpropyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-97-6 CAPLUS
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[(2-hydroxy-2-phenylethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-98-7 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(3-methylbutyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-99-8 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[[[1-(hydroxymethyl)-3-methylbutyl]amino]carbonyl]amino]-, (2S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 253324-00-4 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 yl]-
 2-[[[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]amino]carbonyl]amino]-,
 (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-01-5 CAPLUS
 CN Propanamide, 2-[[[(3-chloropropyl)amino]carbonyl]amino]-N-[(7S)-6,7-
 dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA
 INDEX
 NAME)

Absolute stereochemistry.




RN 253324-02-6 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(octylamino)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 253324-03-7 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(1,1,3,3-tetramethylbutyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 253324-04-8 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(1-methylbutyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-05-9 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[[[1-(hydroxymethyl)butyl]amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-06-0 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(1,3-dimethylbutyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 253324-07-1 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]carbonyl]amino]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-08-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[[(2-methylbutyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-09-3 CAPLUS


CN 4-Morpholinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-10-6 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[2-(2-hydroxyethoxy)ethyl]amino]carbonyl]amino]-, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 253324-11-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 253324-12-8 CAPLUS
 CN Propanamide, 2-[[(butylmethylamino) carbonyl]amino]-N-[(7S)-6,7-dihydro-
 5-
 methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-13-9 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[1-(hydroxymethyl)cyclopentyl]amino]carbonyl]amino]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-14-0 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[4-hydroxybutyl]amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 253324-15-1 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[1-(hydroxymethyl)-2-methylpropyl]amino]carbonyl]amino]-, (2S)-
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-16-2 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[2-hydroxycyclohexyl]amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 253324-17-3 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[hydroxy(1-methylethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA
 INDEX
 NAME)

Absolute stereochemistry.



RN 253324-18-4 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[hydroxy(phenylmethyl)amino]carbonyl]amino]-, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 253324-19-5 CAPLUS

CN L-Alaninamide, L-valyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-20-8 CAPLUS

CN L-Alaninamide, (2S)-2-phenylglycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-21-9 CAPLUS

CN L-Alaninamide, N-(3,5-difluorophenyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-22-0 CAPLUS


CN L-Alaninamide, L-threonyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-23-1 CAPLUS
 CN L-Alaninamide, D-valyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-24-2 CAPLUS
 CN L-Alaninamide, (2R)-2-phenylglycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253324-31-1 CAPLUS
 CN Propanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-32-2 CAPLUS

CN Butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)amino]-1-methyl-2-oxoethyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-34-4 CAPLUS

CN Ethanethioic acid, S-[1-[[[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2-methylpropyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-35-5 CAPLUS

CN L-Alaninamide, 2-phenyl-N-(trifluoroacetyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-36-6 CAPLUS

CN L-Alaninamide, N-methyl-L-valyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-38-8 CAPLUS

CN L-Alaninamide, 4,4,4,4',4',4'-hexafluorovalyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-40-2 CAPLUS

CN Butanamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-mercapto-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-41-3 CAPLUS

CN L-Alaninamide, 4,4,4-trifluorovalyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-42-4 CAPLUS

CN L-Alaninamide, 5,5,5-trifluoronorvalyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-43-5 CAPLUS

CN Butanamide, 2-amino-N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253324-50-4 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-51-5 CAPLUS

CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-52-6 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-53-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-68-4 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]- α -phenyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 253324-73-1 CAPLUS

CN L-Alaninamide, (2S)-2-(3,5-difluorophenyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-74-2 CAPLUS

CN L-Alaninamide, (2R)-2-(3,5-difluorophenyl)glycyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-82-2 CAPLUS


CN L-Alaninamide, 5,5,5-trifluoro-D-norvalyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-83-3 CAPLUS
 CN L-Alaninamide, 5,5,5-trifluoro-L-norvalyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253324-84-4 CAPLUS
 CN Butanamide, 2-amino-N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253324-85-5 CAPLUS
 CN Butanamide, 2-amino-N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253328-98-2 CAPLUS

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209994-99-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)

RN 209994-99-0 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P
 209984-38-3P 209984-41-8P 253324-54-8P
 253324-55-9P 253324-56-0P 253325-01-8P
 253325-02-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-54-8 CAPLUS

CN Carbamic acid, [(1R)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-55-9 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253324-56-0 CAPLUS


CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253325-01-8 CAPLUS
 CN L-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253325-02-9 CAPLUS
 CN L-Alaninamide, L-valyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:819352 CAPLUS Full-text

DN 132:64533

TI Preparation of cyclic amino acid compounds for inhibiting β -amyloid peptide release and/or its synthesis

IN Audia, James E.; Thompson, Richard C.; Wilkie, Stephen C.; Britton, Thomas

C.; Porter, Warren J.; Huffman, George W.; Latimer, Lee H.

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 271 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9967220	A1	19991229	WO 1999-US14007	19990621
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325388	AA	19991229	CA 1999-2325388	19990621
	AU 9952047	A1	20000110	AU 1999-52047	19990621
	EP 1089981	A1	20010411	EP 1999-937164	19990621
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518482	T2	20020625	JP 2000-555874	19990621
	US 6509331	B1	20030121	US 1999-337484	19990621
	US 2003153550	A1	20030814	US 2002-267017	20021007
PRAI	US 1998-102728	A2	19980622		
	US 1998-155265P	P	19980622		
	US 1999-337484	A3	19990621		
	WO 1999-US14007	W	19990621		

OS MARPAT 132:64533

AB Compds. $R_1(Z)mNH(Y)nW$ [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR₂CONH or (CHR₂')aNH, where R₂ = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, R₂' = H or R₂; R₁ = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl, Z = -T-CX'X''CO, where T is selected from the group consisting of a bond covalently linking R₁ to -CX'X''-, oxygen, sulfur and -NR₆ (R₆ = H, acyl, alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X'' together form an oxo group; m = 0 or 1; n = 1 or 2] were prepared for inhibition of β -amyloid peptide release and/or its synthesis. Thus, 1-(L-alaninylamino)-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one was prepared via coupling of N-tert-butoxycarbonyl-L-alanine with 1-amino-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one. Compds. of the invention inhibit β -amyloid peptide production by at least 30% as compared to the control when employed at 10 μ g/mL.

IT 209994-99-0P 228877-30-3P 228877-32-5P

228877-95-0P 253185-47-6P 253185-49-8P

253185-51-2P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use);


BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid
peptide release)

RN 209994-99-0 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-
7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-30-3 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-
7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-32-5 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-
7-yl)-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253185-47-6 CAPLUS


CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-49-8 CAPLUS
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253185-51-2 CAPLUS
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 228877-28-9P 228877-29-0P 228877-31-4P
228877-58-5P 253185-46-5P 253185-48-7P
253185-50-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)


RN 228877-28-9 CAPLUS

CN Carbamic acid, [(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.




RN 228877-29-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)
(CA

INDEX NAME)


Absolute stereochemistry.



RN 228877-31-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS


CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-46-5 CAPLUS
 CN Carbamic acid, [(1R)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253185-48-7 CAPLUS
 CN Carbamic acid, [(1R)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253185-50-1 CAPLUS

CN Carbamic acid, [(1R)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:819351 CAPLUS Full-text
DN 132:64532

TI Preparation of cyclic amino acid compounds for inhibiting β -amyloid peptide release and/or its synthesis

IN Audia, James E.; Porter, Warren J.; Thompson, Richard C.; Wilkie, Stephen C.; Stack, Douglas R.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 287 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9967219	A1	19991229	WO 1999-US14096	19990622
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2324474	AA	19991229	CA 1999-2324474	19990622
	AU 9947079	A1	20000110	AU 1999-47079	19990622
	EP 1089977	A1	20010411	EP 1999-930566	19990622
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002518481	T2	20020625	JP 2000-555873	19990622
	US 6552013	B1	20030422	US 1999-338121	19990622
	US 2003149022	A1	20030807	US 2002-326081	20021223
PRAI	US 1999-102507	A2	19980622		
	US 1998-150704P	P	19980930		
	US 1998-162757	A2	19980930		
	US 1998-160067P	P	19980622		
	US 1999-338121	A3	19990622		
	WO 1999-US14096	W	19990622		

OS MARPAT 132:64532

AB Compds. R1ZNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl; Z is represented by -T-CX'X''V- where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H, acyl, alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X'' together form an oxo group, V is alkylene or substituted alkylene or R1 and Z together form aryl or (un)substituted cycloalkyl, cycloalkenyl, or heterocyclyl; n = 1 or 2] were prepared for inhibition of β -amyloid peptide release and/or its synthesis. Thus, 5-(S)-[N'-(2-(3,5-difluorophenyl)ethyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prepared by reductive alkylation of 5-(S)-(L-alaninyl)amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride with 3,5-difluorophenylacetaldehyde using sodium

cyanoborohydride. Compds. of the invention inhibit β -amyloid peptide production by at least 30% as compared to the control when employed at 10 μ g/mL.

IT 253161-81-8P 253161-91-0P 253161-92-1P
253161-93-2P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)

RN 253161-81-8 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[(1R,2S)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-91-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[(1S,2S)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-92-1 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[[(1S,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-93-2 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[[(1R,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 209984-35-0P 209984-36-1P 209984-39-4P
 209984-40-7P 253135-42-1P 253161-60-3P
 253161-61-4P 253161-62-5P 253161-63-6P
 253161-64-7P 253161-65-8P 253161-66-9P
 253161-67-0P 253161-68-1P 253161-69-2P
 253161-70-5P 253161-71-6P 253161-72-7P
 253161-73-8P 253161-74-9P 253161-76-1P
 253161-77-2P 253161-78-3P 253161-82-9P
 253161-83-0P 253161-84-1P 253161-85-2P
 253161-86-3P 253161-95-4P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclic amino acid compds. for inhibiting β -amyloid
 peptide release)

RN 209984-35-0 CAPLUS
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-39-4 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253135-42-1 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253161-60-3 CAPLUS

CN Propanamide, 2-[[2-(3,5-difluorophenyl)ethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-61-4 CAPLUS


CN Propanamide, 2-[[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-62-5 CAPLUS
 CN Propanamide, 2-[[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-N-
 [(7S)-
 6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 253161-63-6 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-
 yl]-
 2-[[2-hydroxy-3-(1-methylethoxy)propyl]amino]-, (2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 253161-64-7 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-
 yl]-
 2-[(2-hydroxybutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-65-8 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[(2,3-dihydroxypropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-66-9 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-67-0 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[(2-hydroxytetradecyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-68-1 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[(2-hydroxyoctyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-69-2 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[(2R)-2-hydroxy-2-(3,4,5-trifluorophenyl)ethyl]amino]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-70-5 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[2-(2S)-2-hydroxy-2-(3,4,5-trifluorophenyl)ethyl]amino]-, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-71-6 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[2-(2R)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-, (2S)-
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-72-7 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[(2S)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-, (2S)-
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-73-8 CAPLUS
 CN Propanamide, 2-[[(2R)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-74-9 CAPLUS
 CN Propanamide, 2-[[(2S)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-76-1 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-77-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[(3-methyl-2-oxobutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-78-3 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[(2S)-2-hydroxy-3-methylbutyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-82-9 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[(2S)-1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl]amino]-,
 monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 253161-83-0 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-
 2-[[(2R)-1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl]amino]-,
 monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 253161-84-1 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-85-2 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[(2-hydroxycyclohexyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-86-3 CAPLUS
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[(4-methylpentyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-95-4 CAPLUS
 CN L-Alaninamide, N-(4-methylpentyl)-L-valyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P
 209984-38-3P 209984-41-8P 209984-42-9P
 209984-43-0P 209984-44-1P 228877-58-5P
 228877-95-0P 253135-43-2P 253161-58-9P
 253161-75-0P 253161-90-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-43-0 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 228877-58-5 CAPLUS
 CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



The chemical structure shows a 1H-indole-3-carboxamide core. At the 1-position of the indole ring, there is a methyl group (Me) and a (S)-1-aminopropan-2-yl group. The (S)-1-aminopropan-2-yl group is depicted with a central carbon atom bonded to a methyl group (Me), an amino group (NH2), and a hydrogen atom (H) with a wedge bond, indicating its stereochemistry. The indole ring has a carboxamide group (NH-C=O) at the 3-position.

RN	253135-43-2	CAPLUS
CN	Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA	
INDEX	NAME)	


Absolute stereochemistry.



RN 253161-58-9 CAPLUS

CN 5,7-Dioxa-10-aza-2-siladodecan-12-amide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2,11-trimethyl-8-(1-methylethyl)-, (8S,11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-75-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-90-9 CAPLUS

CN Naphth[2,1-d]oxazole-3(2H)-acetamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]-3a,4,5,9b-tetrahydro- α -methyl-2-oxo-,
(α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:819249 CAPLUS Full-text
DN 132:64531

TI Preparation of cyclic amino acid compounds for inhibiting β -amyloid peptide release and/or its synthesis

IN Audia, James E.; Dressman, Bruce A.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966934	A1	19991229	WO 1999-US14211	19990622
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2324475	AA	19991229	CA 1999-2324475	19990622
	AU 9947104	A1	20000110	AU 1999-47104	19990622
	EP 1093372	A1	20010425	EP 1999-930600	19990622
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002518451	T2	20020625	JP 2000-555620	19990622
PRAI	US 1998-102507	A2	19980622		
	US 1998-164451	A2	19980930		
	WO 1999-US14211	W	19990622		
OS	MARPAT 132:64531				
AB	Compds. R'R'NCH ₂ CONH(Y)nW and R':NC(:R ₁)CONH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR ₂ CONH, where R ₂ = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R ₁ and R' form a nitrogen-containing heterocycle; R' = H, alkyl, substituted alkyl, aryl; n = 1 or 2] were prepared for inhibition of β -amyloid peptide release and/or its synthesis. Thus, 5-(S)-[N'-(L-prolyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prepared via coupling of N-(N'-tert-butoxycarbonyl-L-prolyl)-L-alanine with 5-(S)-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. Compds. of the invention inhibit β -amyloid peptide production by at least 30% as compared to the control when employed at 10 μ g/mL.				
IT	209984-35-0P	209984-36-1P	209984-39-4P		
	209984-40-7P	209984-43-0P	209984-44-1P		
	253135-42-1P	253136-07-1P	253136-11-7P		
	253136-15-1P	253136-19-5P	253136-20-8P		
	253136-23-1P	253136-27-5P	253136-32-2P		
	253136-36-6P	253136-39-9P	253136-41-3P		
	253136-43-5P	253136-45-7P	253136-52-6P		
	253136-53-7P	253136-61-7P	253136-65-1P		
	253136-66-2P	253136-74-2P	253136-75-3P		
	253194-30-8P	253194-32-0P	253194-34-2P		

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclic amino acid compds. for inhibiting β -amyloid
 peptide release)
 RN 209984-35-0 CAPLUS
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-39-4 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-40-7 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA
 INDEX NAME)


Absolute stereochemistry.



● HCl

RN 253135-42-1 CAPLUS
 CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




● HCl

RN 253136-07-1 CAPLUS

CN L-Alaninamide, L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-11-7 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-15-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 253136-19-5 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-20-8 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-23-1 CAPLUS

CN L-Alaninamide, (4S)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-27-5 CAPLUS

CN L-Alaninamide, (4R)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-32-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-36-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-39-9 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-41-3 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-43-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-45-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-52-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-53-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-61-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-

, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-65-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-


, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-66-2 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-74-2 CAPLUS
CN 2-Quinolinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-75-3 CAPLUS
CN 2-Piperidinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253194-30-8 CAPLUS

Absolute stereochemistry.




CN 2-Quinolinescarboxamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN 2-Quinolinescarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)

RN 253136-51-5 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-3,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P
209984-38-3P 209984-41-8P 209984-42-9P
228877-58-5P 228877-95-0P 253135-43-2P
253136-06-0P 253136-10-6P 253136-14-0P
253136-18-4P 253136-21-9P 253136-26-4P
253136-31-1P 253136-34-4P 253136-38-8P
253136-42-4P 253136-59-3P 253136-63-9P
253194-29-5P 253194-31-9P 253194-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting β -amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253135-43-2 CAPLUS

CN Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-06-0 CAPLUS

CN L-Alaninamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-10-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-14-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-18-4 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 1-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-

6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-

3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-21-9 CAPLUS

CN L-Alaninamide, (4S)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-L-


prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 253136-26-4 CAPLUS
 CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-
 L-
 prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-31-1 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-
 5H-
 dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-
 dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253136-34-4 CAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-
 oxo-
 5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-
 2,3-
 dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-38-8 CAPLUS

CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-42-4 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-59-3 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-

5H-

dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-63-9 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-

dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253194-29-5 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahy-

dro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-31-9 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-33-1 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:425778 CAPLUS Full-text
 DN 131:73572
 TI Preparation of annelated caprolactams as inhibitors of β -amyloid
 release and/or synthesis.
 IN Audia, James E.; Mabry, Thomas E.; Nissen, Jeffrey S.; Mcdaniel, Stacey
 L.
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company
 SO PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932453	A1	19990701	WO 1998-US22637	19981029
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6635632	B1	20031021	US 1997-996422	19971222
	CA 2307221	AA	19990701	CA 1998-2307221	19981029
	AU 9912777	A1	19990712	AU 1999-12777	19981029
	BR 9812773	A	20001010	BR 1998-12773	19981029
	EP 1042298	A1	20001011	EP 1998-956198	19981029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003521438	T2	20030715	JP 2000-525390	19981029
	US 2002068741	A1	20020606	US 2001-915263	20010726
	US 2002052359	A1	20020502	US 2001-915480	20010727
	US 6544978	B2	20030408		
	US 2002111343	A1	20020815	US 2001-915547	20010727
	US 2002115652	A1	20020822	US 2001-915362	20010727
	US 6541466	B2	20030401		
	US 2002123486	A1	20020905	US 2001-915342	20010727
	US 6632811	B2	20031014		
	US 2002137738	A1	20020926	US 2001-915564	20010727
	US 6559141	B2	20030506		
	US 2002151538	A1	20021017	US 2001-915379	20010727
	US 6579867	B2	20030617		
	US 2002173504	A1	20021121	US 2001-915519	20010727
	US 2002045747	A1	20020418	US 2001-916282	20010730
	US 2002055500	A1	20020509	US 2001-916440	20010730
	US 6653303	B1	20031125	US 2003-336824	20030106
	US 6667305	B1	20031223	US 2003-336745	20030106
	US 6683075	B1	20040127	US 2003-336806	20030106
	US 2004043977	A1	20040304	US 2003-336687	20030106
	US 2004058900	A1	20040325	US 2003-336767	20030106
PRAI	US 1996-64851P	P	19961223		
	US 1997-996422	A	19971222		
	US 1998-102726	A	19980622		
	US 1996-780025	A	19961223		

WO 1998-US22637 W 19981029
 US 2001-915342 A3 20010727
 US 2001-915362 A3 20010727
 US 2001-915379 A3 20010727
 US 2001-915480 A3 20010727
 US 2001-915564 A3 20010727
 OS MARPAT 131:73572
 GI




AB R1(NHCHR2CO)nNHW [W = Q1, Q2, etc.; R1 = H, blocking group; R2 = H, (substituted) alkyl, alkenyl, alkynyl, acyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; A, B = atoms to form aryl, (substituted) cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic ring; R3 = H, (substituted) alkyl, alkenyl, alkynyl, acyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; R4 = (substituted) alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; m, n = 0-2], were prepared. Thus, 7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one (preparation given) in PhMe was treated with Bu nitrite; the mixt at 0° was treated with KN(SiMe3)2 followed by 1 h stirring to give 80% 7-methyl-5-oximo-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. The latter was hydrogenated in EtOH over Pd/C at 35 psi to give 61% 5-amino-7-methyl-5,7- dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride. Title compds. at 10 µg/mL inhibit β-amyloid production by ≥30%.

IT 209984-35-0P 209984-36-1P 209984-39-4P
 209984-40-7P 209984-43-0P 209984-44-1P
 209985-07-9P 209985-08-0P 209985-09-1P
 209994-99-0P 228877-28-9P 228877-29-0P
 228877-30-3P 228877-31-4P 228877-32-5P
 228877-33-6P 228877-34-7P 228877-35-8P
 228877-36-9P 228877-37-0P 228877-38-1P
 228877-39-2P 228877-40-5P 228877-41-6P
 228877-42-7P 228877-43-8P 228877-44-9P
 228877-45-0P 228877-46-1P 228877-47-2P
 228877-48-3P 228877-49-4P 228877-50-7P
 228877-51-8P 228877-52-9P 228877-53-0P
 228877-54-1P 228877-58-5P 228877-59-6P
 228877-64-3P 228877-95-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of annelated caprolactams as inhibitors of β-amyloid release and/or synthesis)

RN 209984-35-0 CAPLUS
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-39-4 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-43-0 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-07-9 CAPLUS
 CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-08-0 CAPLUS
 CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-09-1 CAPLUS
 CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 209994-99-0 CAPLUS
 CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-28-9 CAPLUS
 CN Carbamic acid, [(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-29-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-30-3 CAPLUS
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-31-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 228877-32-5 CAPLUS
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-33-6 CAPLUS

CN Carbamic acid, [(1S)-2-[(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-34-7 CAPLUS


CN Propanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-35-8 CAPLUS
 CN Carbamic acid, [(1S)-2-[(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-36-9 CAPLUS
 CN Propanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228877-37-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-38-1 CAPLUS

CN Propanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-39-2 CAPLUS

CN Carbamic acid, [(1S)-2-[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-40-5 CAPLUS

CN Propanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-41-6 CAPLUS

CN Carbamic acid, [(1S)-2-[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-42-7 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-43-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-44-9 CAPLUS

CN Butanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-45-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-46-1 CAPLUS

CN Butanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-47-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-48-3 CAPLUS

CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-49-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[[9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-50-7 CAPLUS

CN Butanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-51-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-52-9 CAPLUS

CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-53-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-54-1 CAPLUS

CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-59-6 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-64-3 CAPLUS

CN Butanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 228877-95-0 CAPLUS
 CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 209984-33-8P 209984-34-9P 209984-37-2P
 209984-38-3P 209984-41-8P 209984-42-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT (Reactant or reagent)
 (preparation of annelated caprolactams as inhibitors of β -amyloid release and/or synthesis)
 RN 209984-33-8 CAPLUS
 CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:608608 CAPLUS Full-text
 DN 129:245485
 TI Preparation of heterocyclic compounds and their use for inhibiting
 β -amyloid peptide release
 IN Thorsett, Eugene D.; Porter, Warren J.; Nissen, Jeffrey S.; Latimer, Lee
 H.; Audia, James E.; Droste, James J.
 PA Athena Neurosciences, Inc., USA; Eli Lilly & Co.
 SO PCT Int. Appl., 392 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9838177	A1	19980903	WO 1998-US3373	19980227
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	ZA 9801627	A	19991005	ZA 1998-1627	19980226
	AU 9866622	A1	19980918	AU 1998-66622	19980227
	EP 968198	A1	20000105	EP 1998-908637	19980227
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	TR 9902071	T2	20000121	TR 1999-9902071	19980227
	BR 9807876	A	20000229	BR 1998-7876	19980227
	JP 2001513107	T2	20010828	JP 1998-537732	19980227
	NO 9904016	A	19991018	NO 1999-4016	19990819
PRAI	US 1997-808263	A1	19970228		
	WO 1998-US3373	W	19980227		
OS	MARPAT 129:245485				
GI					




AB Disclosed are modified heterocyclic di- and tripeptide analogs which inhibit β -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compns. comprising a compound which inhibits β -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compns. Title compds., e.g. I,

were prepared in a multistep synthesis and inhibited β -amyloid peptide production by at least 30% as compared to control.

IT 209984-35-0P 209984-36-1P 209984-39-4P
209984-40-7P 209984-43-0P 209984-44-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic compds. and their use for inhibiting β -amyloid peptide release)
RN 209984-35-0 CAPLUS
CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS
CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-39-4 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 209984-33-8P 209984-34-9P 209984-37-2P

209984-38-3P 209984-41-8P 209984-42-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of heterocyclic compds. and their use for inhibiting
β-amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:479505 CAPLUS Full-text

DN 129:122870

TI Preparation of cycloalkyl, lactam, lactone and related compounds for inhibiting β -amyloid peptide release and/or its synthesis

IN Wu, Jing; Tung, Jay S.; Thorsett, Eugene D.; Pleiss, Michael A.; Nissen, Jeffrey S.; Neitz, Jeffrey; Latimer, Lee H.; John, Varghese; Freedman, Stephen; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry,

Thomas

E.; Dressman, Bruce A.; Cwi, Cynthia L.; Droste, James J.; Henry, Steven S.; Mcdaniel, Stacey L.; Scott, William Leonard; Stucky, Russell D.; Porter, Warren J.

PA Athena Neurosciences, Inc., USA; Eli Lilly & Co.

SO PCT Int. Appl., 889 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9828268	A2	19980702	WO 1997-US22986	19971222
	WO 9828268	A3	19981008		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9711537	A	19980625	ZA 1997-11537	19971222
	AU 9857007	A1	19980717	AU 1998-57007	19971222
	AU 749658	B2	20020627		
	EP 951466	A2	19991027	EP 1997-953208	19971222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1242007	A	20000119	CN 1997-180901	19971222
	BR 9714517	A	20000704	BR 1997-14517	19971222
	JP 2000511932	T2	20000912	JP 1998-528867	19971222
	NZ 335583	A	20010330	NZ 1997-335583	19971222
	MX 9905844	A	20000731	MX 1999-5844	19990621
	NO 9903098	A	19990820	NO 1999-3098	19990622
	US 2002045747	A1	20020418	US 2001-916282	20010730
	US 2002055500	A1	20020509	US 2001-916440	20010730
	US 6653303	B1	20031125	US 2003-336824	20030106
	US 6667305	B1	20031223	US 2003-336745	20030106
	US 6683075	B1	20040127	US 2003-336806	20030106
	US 2004043977	A1	20040304	US 2003-336687	20030106
	US 2004058900	A1	20040325	US 2003-336767	20030106
PRAI	US 1996-64851P	P	19961223		
	US 1996-64851P	P	19961223		
	US 1996-780025	A1	19961223		
	US 1997-996422	A3	19971222		
	WO 1997-US22986	W	19971222		
	US 2001-915342	A3	20010727		
	US 2001-915362	A3	20010727		
	US 2001-915379	A3	20010727		

US 2001-915480 A3 20010727

US 2001-915564 A3 20010727

OS MARPAT 129:122870

AB Disclosed are compds. $R_1ZmNHYnCHpR_2C(X)R_3$ [R_1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl or aryl, heteroaryl, or heterocyclic; R_2 and R_3 form a cycloalkyl, cycloalkenyl, heterocyclic, substituted cycloalkyl, or substituted cycloalkenyl ring which is optionally fused; X = oxo, thioxo, hydroxyl, thiol, or hydro; Y = CHR_4CONH where R_4 = (un)substituted alkyl, alkenyl, or alkynyl or cycloalkyl, aryl, heteroaryl, or heterocyclic; Z is $TCX'X''CO$ where T is a bond, O, S, NR_5 (R_5 = H, acyl, alkyl, aryl, or heteroaryl), X' and X'' are H, OH, or F or $X'X''$ = oxo; $m, p = 0, 1$; $n = 0, 1, 2$] which inhibit β -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Thus, 3-[[N'-(3,4-methylenedioxyphenylacetyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prepared by coupling of 3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 3,4-methylenedioxyphenylacetic acid.

IT 209994-99-0 209995-66-4 209995-67-5

209995-68-6 209995-69-7 209995-70-0

209995-71-1

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of cycloalkyl, lactam, lactone and related compds. for inhibiting β -amyloid peptide release and/or its synthesis)


RN 209994-99-0 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 209995-67-5 CAPLUS

CN Benzeneacetamide, α -amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-68-6 CAPLUS

CN Pentanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-69-7 CAPLUS

CN Cyclohexaneacetamide, α -amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-70-0 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-hydroxy-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-71-1 CAPLUS

CN 2-Thiopheneacetamide, α -amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-35-0P
 209984-36-1P 209984-37-2P 209984-38-3P
 209984-39-4P 209984-40-7P 209984-41-8P
 209984-42-9P 209984-43-0P 209984-44-1P
 209985-01-3P 209985-02-4P 209985-03-5P
 209985-04-6P 209985-05-7P 209985-06-8P
 209985-07-9P 209985-08-0P 209985-09-1P
 209985-10-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of cycloalkyl, lactam, lactone and related compds. for
 inhibiting β -amyloid peptide release and/or its synthesis)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-
 dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-36-1 CAPLUS

CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-39-4 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS


CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-43-0 CAPLUS
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-01-3 CAPLUS
 CN Propanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-02-4 CAPLUS
 CN Propanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-03-5 CAPLUS
 CN Propanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-04-6 CAPLUS
 CN Propanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-05-7 CAPLUS
 CN Butanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-06-8 CAPLUS
 CN Butanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209985-07-9 CAPLUS

CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209985-08-0 CAPLUS

CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-09-1 CAPLUS
 CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209985-10-4 CAPLUS
 CN Butanamide, 2-amino-N-(3-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT	209984-56-5P	209984-57-6P	209984-58-7P
	209984-59-8P	209984-60-1P	209984-61-2P
	209984-62-3P	209984-63-4P	209984-64-5P
	209984-65-6P	209984-66-7P	209984-67-8P
	209984-68-9P	209984-69-0P	209984-70-3P
	209984-71-4P	209984-72-5P	209984-73-6P
	209984-74-7P	209984-75-8P	209984-76-9P
	209984-77-0P	209984-78-1P	209984-79-2P
	209984-80-5P	209984-81-6P	209984-82-7P
	209984-83-8P	209984-84-9P	209984-85-0P
	209984-86-1P	209984-87-2P	209984-88-3P
	209984-89-4P	209984-90-7P	209984-91-8P
	209984-92-9P	209984-93-0P	209984-94-1P
	209992-82-5P	209992-83-6P	209992-84-7P
	209992-85-8P	209992-86-9P	209992-87-0P
	209992-88-1P	209992-89-2P	209992-90-5P
	209992-91-6P	209992-92-7P	209992-93-8P
	209992-94-9P	209992-95-0P	209992-96-1P
	209992-97-2P	209992-98-3P	209992-99-4P
	209993-00-0P	209993-01-1P	209993-02-2P
	209993-03-3P	209993-04-4P	209993-05-5P
	209993-06-6P	209993-07-7P	209993-08-8P
	209993-09-9P	209993-10-2P	209993-11-3P
	209993-12-4P	209993-13-5P	209993-14-6P
	209993-15-7P	209993-16-8P	209993-17-9P
	209993-18-0P	209993-19-1P	209993-20-4P
	209993-21-5P	209993-22-6P	209993-23-7P
	209993-24-8P	209993-25-9P	209993-26-0P
	209993-27-1P	209993-28-2P	209993-29-3P
	209993-30-6P	209993-31-7P	209993-32-8P
	209993-33-9P	209993-34-0P	209993-35-1P
	209993-36-2P	209993-37-3P	209993-38-4P
	209993-39-5P	209993-40-8P	209993-41-9P
	209993-42-0P	209993-43-1P	209993-44-2P
	209993-45-3P	209993-46-4P	209993-47-5P
	209993-48-6P	209993-49-7P	209993-50-0P
	209993-51-1P	209993-52-2P	209993-53-3P
	209993-54-4P	209993-55-5P	209993-56-6P
	209993-57-7P	209993-58-8P	209993-59-9P

209993-60-2P 209993-61-3P 209993-62-4P
 209993-63-5P 209993-64-6P 209993-65-7P
 209993-66-8P 209993-67-9P 209993-68-0P
 209993-69-1P 209993-70-4P 209993-71-5P
 209993-72-6P 209993-73-7P 209993-74-8P
 209993-75-9P 209993-76-0P 209993-77-1P
 209993-78-2P 209993-79-3P 209993-80-6P
 209993-81-7P 209993-82-8P 209993-83-9P
 209993-84-0P 209993-85-1P 209993-86-2P
 209993-87-3P 209993-88-4P 209993-89-5P
 209993-90-8P 209993-91-9P 209993-92-0P
 209993-93-1P 209993-94-2P 209993-95-3P
 209993-96-4P 209993-97-5P 209993-98-6P
 209993-99-7P 209994-00-3P 209994-01-4P
 209994-02-5P 209994-03-6P 209994-04-7P
 209994-05-8P 209994-06-9P 209994-07-0P
 209994-08-1P 209994-09-2P 209994-10-5P
 209994-11-6P 209994-12-7P 209994-13-8P
 209994-14-9P 209994-15-0P 209994-16-1P
 209994-17-2P 209994-18-3P 209994-19-4P
 209994-20-7P 209994-21-8P 209994-22-9P
 209994-23-0P 209994-24-1P 209994-25-2P
 209994-26-3P 209994-27-4P 209994-28-5P
 209994-29-6P 209994-30-9P 209994-31-0P
 209994-32-1P 209994-33-2P 209994-34-3P
 209994-35-4P 209994-36-5P 209994-37-6P
 209994-38-7P 209994-39-8P 209994-40-1P
 209994-41-2P 209994-42-3P 209994-43-4P
 209994-44-5P 209994-45-6P 209994-46-7P
 209994-47-8P 209994-48-9P 209994-49-0P
 209994-50-3P 209994-51-4P 209994-52-5P
 209994-53-6P 209994-54-7P 209994-55-8P
 209994-56-9P 209994-57-0P 209994-58-1P
 209994-59-2P 209994-60-5P 209994-61-6P
 209994-62-7P 209994-63-8P 209994-64-9P
 209994-65-0P 209994-66-1P 209994-67-2P
 209994-68-3P 209994-69-4P 209994-70-7P
 209994-71-8P 209994-72-9P 209994-73-0P
 209994-74-1P 209994-75-2P 209994-76-3P
 209994-77-4P 209994-78-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cycloalkyl, lactam, lactone and related compds. for inhibiting β -amyloid peptide release and/or its synthesis)

RN 209984-56-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-57-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 209984-58-7 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 209984-59-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-60-1 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-3,5-difluoro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 209984-61-2 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 209984-62-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-63-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-64-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-5-(methoxyacetyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209984-65-6 CAPLUS

CN 5H-Dibenz[b,d]azepine-5-carboxylic acid, 7-[[(2S)-2-[[(3,5-difluorophenyl) acetyl] amino]-1-oxopropyl] amino]-6,7-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-66-7 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[[5-(3,3-dimethyl-1-oxobutyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-67-8 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-5-(4-morpholinylacetyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-68-9 CAPLUS
 CN Butanamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 209984-69-0 CAPLUS
 CN Cyclopentaneacetamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-α-hydroxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-70-3 CAPLUS
 CN Butanamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-71-4 CAPLUS
 CN Butanamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-72-5 CAPLUS
 CN Cyclopentaneacetamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-73-6 CAPLUS
 CN Cyclopentaneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-α-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-74-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-75-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-76-9 CAPLUS

CN Butanamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-2-hydroxy-3-methyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-77-0 CAPLUS

CN Butanamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-2-hydroxy-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-78-1 CAPLUS

CN Butanamide, N-[(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-2-hydroxy-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-79-2 CAPLUS

CN Propanamide, N-((6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(4-phenyl-1,2,5-oxadiazol-3-yl)amino])- , (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-80-5 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-81-6 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-82-7 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[6,7-dihydro-6-oxo-5-(2,2,2-trifluoroethyl)-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-83-8 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[[5-(cyclohexyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-84-9 CAPLUS
 CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-85-0 CAPLUS
 CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-86-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(2-fluoro-6,7-dihydro-5-methyl-6-

oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-87-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-

dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-88-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-89-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-90-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-3,5-difluoro- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-91-8 CAPLUS


CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[[5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-92-9 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-93-0 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-94-1 CAPLUS
CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-[[(3-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]- α -hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-82-5 CAPLUS

CN Cyclopentaneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-83-6 CAPLUS

CN Cyclopentanepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-84-7 CAPLUS


CN Cyclohexaneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209992-85-8 CAPLUS
CN Butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209992-86-9 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-87-0 CAPLUS

CN Benzeneacetamide, 3-bromo-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-88-1 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209992-89-2 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209992-90-5 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209992-91-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209992-92-7 CAPLUS
 CN Hexanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209992-93-8 CAPLUS
 CN Heptanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-94-9 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,4-difluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209992-95-0 CAPLUS

CN Cyclopropaneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-96-1 CAPLUS

CN 2-Cyclopentene-1-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-97-2 CAPLUS

CN Cyclohexanepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209992-98-3 CAPLUS


CN Butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209992-99-4 CAPLUS
 CN 6-Octenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,7-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-00-0 CAPLUS
 CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-gamma-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-01-1 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-02-2 CAPLUS

CN 4-Pentenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-03-3 CAPLUS

CN Pentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-04-4 CAPLUS


CN 2-Thiopheneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-05-5 CAPLUS
 CN 2-Thiophenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-06-6 CAPLUS
 CN Benzenebutamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-07-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,4-difluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209993-08-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,6-difluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209993-09-9 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-10-2 CAPLUS
 CN Tricyclo[3.3.1.1.3,7]decane-1-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-11-3 CAPLUS
 CN Cyclohexanepentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-12-4 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[methylthio]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-13-5 CAPLUS

CN 2-Thiophenepentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 209993-14-6 CAPLUS

CN Bicyclo[2.2.1]heptane-2-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-
oxo-
5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, (1S,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209993-15-7 CAPLUS

CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-


7-yl)amino]carbonyl]-3-ethylpentyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 209993-16-8 CAPLUS

CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-


7-yl)amino]carbonyl]-3-methylpentyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 209993-17-9 CAPLUS


CN Benzeneacetamide, N-[1-(cyclopropylmethyl)-2-[(6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl)amino]-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)




RN 209993-18-0 CAPLUS

CN Benzeneacetamide, N-[3-cyclohexyl-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]propyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 209993-19-1 CAPLUS


CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]-5-fluoropentyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 209993-20-4 CAPLUS


CN Cyclohexaneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-

dibenz[b,d]azepin-7-yl) amino]carbonyl]-3-ethylpentyl]- (9CI) (CA INDEX NAME)




RN 209993-21-5 CAPLUS

CN Cyclopropaneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]-3-ethylpentyl]- (9CI) (CA INDEX NAME)




RN 209993-22-6 CAPLUS

CN Hexanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-4-ethyl-2-[(3-methyl-1-oxobutyl) amino]- (9CI) (CA INDEX NAME)



RN 209993-23-7 CAPLUS


CN Benzeneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]-3-ethylpentyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209993-24-8 CAPLUS

CN Benzeneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-


7-yl]amino]carbonyl]-3-ethylpentyl]-3,4-difluoro- (9CI) (CA INDEX NAME)



RN 209993-25-9 CAPLUS

CN Benzeneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-


7-yl]amino]carbonyl]-3-ethylpentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 209993-26-0 CAPLUS


CN Benzeneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-

7-yl]amino]carbonyl]-3-methylpentyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 209993-27-1 CAPLUS

CN Cyclopentaneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-3-methylpentyl]- (9CI) (CA INDEX NAME)




RN 209993-28-2 CAPLUS

CN Cyclohexaneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-3-methylpentyl]- (9CI) (CA INDEX NAME)




RN 209993-29-3 CAPLUS

CN Cyclopropaneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-3-methylpentyl]- (9CI) (CA INDEX NAME)




RN 209993-30-6 CAPLUS

CN 2-Thiopheneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-methylpentyl]- (9CI) (CA INDEX NAME)




RN 209993-31-7 CAPLUS

CN Hexanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-4-methyl-2-[(3-methyl-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)




RN 209993-32-8 CAPLUS


CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-methylpentyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 209993-33-9 CAPLUS
 CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-methylpentyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 209993-34-0 CAPLUS
 CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-methylpentyl]-3,4-difluoro- (9CI) (CA INDEX NAME)



RN 209993-35-1 CAPLUS
 CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-methylpentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 209993-36-2 CAPLUS
 CN Benzeneacetamide, N-[3-cyclohexyl-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]propyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 209993-37-3 CAPLUS

CN Cyclohexanebutanamide, α -[(cyclopentylacetyl)amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)



RN 209993-38-4 CAPLUS


CN Cyclohexanebutanamide, α -[(cyclohexylacetyl)amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)



RN 209993-39-5 CAPLUS


CN Cyclohexanebutanamide, α -[(cyclopropylacetyl)amino]-N-(6,7-dihydro-5-

methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)




RN 209993-40-8 CAPLUS

CN Cyclohexanebutanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-α-[(3-methyl-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)



RN 209993-41-9 CAPLUS


CN Benzeneacetamide, N-[3-cyclohexyl-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]propyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 209993-42-0 CAPLUS


CN Benzeneacetamide, N-[3-cyclohexyl-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]propyl]-3,4-difluoro- (9CI) (CA

INDEX NAME)




RN 209993-43-1 CAPLUS

CN Benzeneacetamide, N-[3-cyclohexyl-1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]propyl]-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 209993-44-2 CAPLUS


CN Benzeneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-5-fluoropentyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 209993-45-3 CAPLUS


CN Cyclopentaneacetamide, N-[1-[[[6,7-dihydro-5-methyl-6-oxo-5H-

dibenz[b,d]azepin-7-yl) amino]carbonyl]-5-fluoropentyl]- (9CI) (CA INDEX NAME)




RN 209993-46-4 CAPLUS

CN Cyclohexaneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]-5-fluoropentyl]- (9CI) (CA INDEX NAME)



RN 209993-47-5 CAPLUS

CN Cyclopropaneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]carbonyl]-5-fluoropentyl]- (9CI) (CA INDEX NAME)




RN 209993-48-6 CAPLUS


CN Hexanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-6-fluoro-2-[(3-methyl-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)

```


RN      209993-49-7  CAPLUS
CN      Benzeneacetamide, N-[1-[[ (6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-
       7-yl)amino]carbonyl]-5-fluoropentyl]-3-(trifluoromethyl)- (9CI)  (CA
INDEX
NAME)
```




RN 209993-50-0 CAPLUS
CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-5-fluoropentyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 209993-51-1 CAPLUS
CN Benzeneacetamide, N-[1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-5-fluoropentyl]-3,4-difluoro- (9CI) (CA INDEX NAME)




RN 209993-52-2 CAPLUS
 CN Benzeneacetamide, N-[1-[[5-fluoropentyl]amino]carbonyl]-5-fluoropentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 209993-53-3 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-54-4 CAPLUS
 CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-55-5 CAPLUS

CN 1-Naphthaleneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-56-6 CAPLUS

CN 1,3-Benzodioxole-5-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-57-7 CAPLUS


CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-58-8 CAPLUS
 CN Octanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-59-9 CAPLUS
 CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-60-2 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-61-3 CAPLUS

CN Benzenepropanamide, 4-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-62-4 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-63-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-64-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,4,5-trifluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209993-65-7 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-66-8 CAPLUS

CN Butanoic acid, 4-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-67-9 CAPLUS


CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[1-oxo-3-[(phenylmethyl)thio]propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-68-0 CAPLUS
 CN Pentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-69-1 CAPLUS
 CN Octanoic acid, 8-[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]-8-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-70-4 CAPLUS
 CN 1H-Indene-2-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]-1-methyl-2-oxoethyl]-2,3-dihydro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-71-5 CAPLUS
 CN Hexanoic acid, 6-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]-1-methyl-2-oxoethyl] amino]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-72-6 CAPLUS

CN 3-Benzofuranacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-73-7 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(1-oxopropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-74-8 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(3-methoxy-1-oxopropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-75-9 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-76-0 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[3-(4-fluorophenoxy)-1-oxopropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-77-1 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[[(4-methylphenyl)sulfonyl]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-78-2 CAPLUS

CN 3-Pentenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-
7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 209993-79-3 CAPLUS
 CN Benzenebutanamide, 2,4-dichloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-80-6 CAPLUS
 CN Propanamide, 2-[[[(2,3-dichlorophenoxy)acetyl]amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-81-7 CAPLUS

CN Benzenepentanamide, 4-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-δ-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-82-8 CAPLUS

CN Butanediamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-83-9 CAPLUS

CN Pentanediamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-N'-(diphenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-84-0 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-85-1 CAPLUS


CN Propanamide, 2-[(cyanoacetyl)amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-86-2 CAPLUS
 CN Butanediamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-87-3 CAPLUS
 CN Propanamide, 2-[[[(2,4-dichlorophenoxy)acetyl]amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-88-4 CAPLUS
 CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[[(2-nitrophenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209993-89-5 CAPLUS
 CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-β-propyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 209993-90-8 CAPLUS
 CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,4-dimethyl-γ-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-91-9 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-

dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-92-0 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,4,6-trifluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209993-93-1 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-fluoro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-94-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-95-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-96-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-97-5 CAPLUS

CN Benzeneacetamide, 2-bromo-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-98-6 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[[4-(phenylmethoxy)phenoxy]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209993-99-7 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[(4-hydroxyphenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-00-3 CAPLUS

CN Pentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-01-4 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-hydroxy- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 209994-02-5 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,4-dimethoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-03-6 CAPLUS
 CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-methoxy-γ-oxo- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-04-7 CAPLUS

CN [1,1'-Biphenyl]-4-butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-γ-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-05-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-06-9 CAPLUS


CN L-Alaninamide, N-acetyl-N-phenylglycyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-07-0 CAPLUS
 CN 3-Thiopheneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-08-1 CAPLUS
 CN Benzenehexanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-09-2 CAPLUS
 CN Cyclohexanebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-10-5 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3,5-trifluoro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-11-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,4,5-trifluoro-
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 209994-12-7 CAPLUS

CN 3-Butenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-13-8 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[3-(methylthio)-1-oxopropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-14-9 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-15-0 CAPLUS
 CN Butanediamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-16-1 CAPLUS
 CN Benzeneacetamide, 4-bromo-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-17-2 CAPLUS
 CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-fluoro-γ-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-18-3 CAPLUS
 CN Propanamide, 2-[[(2-chlorophenoxy) acetyl] amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-19-4 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]-1-methyl-2-oxoethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-20-7 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino]-1-methyl-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 209994-21-8 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-22-9 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenoxy)acetyl]amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-23-0 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[(3-methylphenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-24-1 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[[4-(1-methylethyl)phenoxy]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-25-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-phenoxy- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 209994-26-3 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[(phenylthio)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-27-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-28-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-29-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-30-9 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-beta-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-31-0 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[(1-oxo-3-phenoxypropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-32-1 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-(trifluoromethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-33-2 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[4-methylphenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-34-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-35-4 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-36-5 CAPLUS

CN Propanamide, 2-[[[(3,4-dichlorophenoxy)acetyl]amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-37-6 CAPLUS

CN Propanamide, N-((6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[4-(2,4-dichlorophenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-38-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-39-8 CAPLUS

CN Benzeneacetamide, 2,4-dichloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-40-1 CAPLUS

CN Benzo[b]thiophene-4-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-

5H-

dibenz[b,d]azepin-7-yl) amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-41-2 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[(methoxyacetyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-42-3 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(ethoxyacetyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-43-4 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(phenoxyacetyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-44-5 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[(3-methoxyphenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-45-6 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-46-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-47-8 CAPLUS

CN Butanediamide, N'-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-48-9 CAPLUS

CN 1,3-Benzodioxole-5-propanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-49-0 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-6-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-50-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-51-4 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-

[[(pentafluorophenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-52-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-53-6 CAPLUS


CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[(3,5-dimethylphenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-54-7 CAPLUS

Absolute stereochemistry.




CN Propanamide, 2-[[(3-chlorophenoxy)acetyl]amino]-N-(6,7-dihydro-5-methyl-
6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

CN1C(=O)c2ccccc2-c3ccccc13C(=O)NCC(=O)[C@H](C)SCC(=O)NCC(=O)COc4ccc(Cl)cc4


CN Benzo[b]thiophene-3-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-
5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 209994-57-0 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3,5-dimethoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-58-1 CAPLUS
 CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,5-dimethyl- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-59-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,4,6-trimethyl-
(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209994-60-5 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-61-6 CAPLUS


CN L-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-β-alanyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-62-7 CAPLUS
 CN 3-Butenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-phenyl-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 209994-63-8 CAPLUS
 CN Butanamide, 4-(acetylamino)-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-64-9 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-65-0 CAPLUS

CN Butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-66-1 CAPLUS

CN 3-Hexenamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 209994-67-2 CAPLUS

CN Benzenepentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-68-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-69-4 CAPLUS

CN Benzenepropanamide, 4-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- β -methyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209994-70-7 CAPLUS

CN Butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-71-8 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[(methylsulfonyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-72-9 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
[[(1-naphthalenyloxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-73-0 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-γ-oxo-4-phenoxy-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-74-1 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-γ-oxo-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-75-2 CAPLUS

CN Benzenepropanamide, 3-(benzoylamino)-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-76-3 CAPLUS

CN Pentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-(hydroxyimino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 209994-77-4 CAPLUS

CN Pentanediamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-N'-(4-methylphenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-78-5 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[[4-(4-ethylphenoxy)phenoxy]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209994-79-6P 209994-80-9P 209994-81-0P
 209994-82-1P 209994-83-2P 209994-84-3P
 209994-85-4P 209994-86-5P 209994-87-6P
 209994-88-7P 209994-89-8P 209994-90-1P
 209994-91-2P 209994-92-3P 209994-93-4P
 209994-94-5P 209994-95-6P 209994-96-7P
 209994-97-8P 209994-98-9P 209995-42-6P
 209995-43-7P 209995-44-8P 209995-45-9P
 209995-46-0P 209995-47-1P 209995-48-2P
 209995-49-3P 209995-50-6P 209995-51-7P
 209995-52-8P 209995-53-9P 209995-54-0P
 209995-55-1P 209995-56-2P 209995-57-3P
 209995-58-4P 209995-59-5P 209995-60-8P
 209995-61-9P 209995-62-0P 209995-63-1P
 209995-64-2P 209995-65-3P 209996-41-8P
 209996-42-9P 209996-43-0P 209996-44-1P
 209996-45-2P 209996-46-3P 209996-47-4P
 209996-48-5P 209996-49-6P 209996-50-9P
 209996-51-0P 209996-52-1P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cycloalkyl, lactam, lactone and related compds. for inhibiting β -amyloid peptide release and/or its synthesis)

RN 209994-79-6 CAPLUS

CN Benzenepropanamide, 3-benzoyl-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-80-9 CAPLUS


CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[4-(hydroxymethyl)phenoxy]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-81-0 CAPLUS
 CN Butanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-82-1 CAPLUS
 CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-83-2 CAPLUS
 CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[(2-methylphenoxy)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-84-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-85-4 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-86-5 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(3-ethoxy-1-oxopropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-87-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3-difluoro- α -hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-88-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,6-difluoro- α -hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-89-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-4-fluoro- α -hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-90-1 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,5-difluoro- α -hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-91-2 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- α -hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209994-92-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 209994-93-4 CAPLUS


CN Benzeneacetamide, 4-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 209994-94-5 CAPLUS
 CN Pentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-hydroxy-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-95-6 CAPLUS
 CN Benzeneacetamide, 4-bromo-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-α-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-96-7 CAPLUS
 CN Propanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209994-97-8 CAPLUS
 CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- α -hydroxy-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209994-98-9 CAPLUS
 CN Hexanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-42-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-3-(methylthio)propyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-43-7 CAPLUS


CN Benzeneacetamide, N-[(1S)-2-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-oxo-1-phenylethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-44-8 CAPLUS
 CN Benzeneacetamide, N-[(1S)-1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-3-methylbutyl]-3,5-difluoro-
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 209995-45-9 CAPLUS
 CN Benzeneacetamide, N-[(1S)-1-cyclohexyl-2-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-46-0 CAPLUS

CN Benzeneacetamide, N-[(1S,2R)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-hydroxypropyl]-3,5-difluoro-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-47-1 CAPLUS

CN 2-Thiopheneacetamide, α -[[[(3,5-difluorophenyl)acetyl]amino]-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-48-2 CAPLUS

CN 2-Thiopheneacetamide, N-[(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-3-(methylthio)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-49-3 CAPLUS

CN 2-Thiopheneacetamide, N-[(1S)-2-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-50-6 CAPLUS

CN 2-Thiopheneacetamide, N-[(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-51-7 CAPLUS

CN 2-Thiopheneacetamide, N-[(1S)-1-cyclohexyl-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-52-8 CAPLUS


CN 2-Thiopheneacetamide, N-[(1S,2R)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-53-9 CAPLUS
 CN 2-Thiopheneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- α -[(2-thienylacetyl)amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-54-0 CAPLUS
 CN Butanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(3-methyl-1-oxobutyl)amino]-4-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-55-1 CAPLUS
CN Benzeneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-
α-[(3-methyl-1-oxobutyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-56-2 CAPLUS
CN Pentanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-4-methyl-2-[(3-methyl-1-oxobutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209995-57-3 CAPLUS
CN Cyclohexaneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-α-[(3-methyl-1-oxobutyl)amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-58-4 CAPLUS

CN Butanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-hydroxy-2-[(3-methyl-1-oxobutyl)amino]-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-59-5 CAPLUS


CN 2-Thiopheneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-α-[(3-methyl-1-oxobutyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-60-8 CAPLUS
 CN Benzeneacetamide, N-[(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-(methylthio)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-61-9 CAPLUS
 CN Benzeneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-
 α -[(phenylacetyl)amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-62-0 CAPLUS
 CN Benzeneacetamide, N-[(1S)-1-[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl) amino] carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209995-63-1 CAPLUS
 CN Benzeneacetamide, N-[(1S)-1-cyclohexyl-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209995-64-2 CAPLUS
 CN Benzeneacetamide, N-[(1S,2R)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209995-65-3 CAPLUS

CN 2-Thiopheneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- α -[(phenylacetyl)amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-41-8 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[(3,7-dimethyl-6-octenyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-42-9 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- β -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-43-0 CAPLUS

CN Butanamide, 4-(2,4-dichlorophenoxy)-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-44-1 CAPLUS

CN Benzenebutanamide, 4-chloro-N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-gamma-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-45-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-46-3 CAPLUS

CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[4-methoxyphenoxy]acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-47-4 CAPLUS

CN L-Alaninamide, N-benzoyl-3-phenyl-beta-alanyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-48-5 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-gamma-oxo-beta-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-49-6 CAPLUS

CN L-Alaninamide, N-(2-methyl-1-oxopropyl)-3-phenyl- β -alanyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209996-50-9 CAPLUS


CN Propanamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-[[1-oxo-3-(phenylsulfonyl)propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209996-51-0 CAPLUS


CN Benzeneacetamide, N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- α -hydroxy- (9CI) (CA INDEX NAME)




RN 209996-52-1 CAPLUS

CN Pentanamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2-hydroxy-4-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 09:27:59 ON 01 JUL 2004)

FILE 'REGISTRY' ENTERED AT 09:28:12 ON 01 JUL 2004

L1 STRUCTURE UPLOADED
L2 30 S L1
L3 699 S L1 FUL

FILE 'CAPLUS' ENTERED AT 09:29:21 ON 01 JUL 2004

L4 23 S L3

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	116.33	272.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.91	-16.91

STN INTERNATIONAL LOGOFF AT 09:30:51 ON 01 JUL 2004